Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:oxanes
go back to main search page
Accession:CHEBI:46942 term browser browse the term
Definition:Any organic heteromonocyclic compoundthat is oxane or its substituted derivatives.
Synonyms:related_synonym: tetrahydropyrans



show annotations for term's descendants           Sort by:
 
Aurothioglucose term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Adipor1 adiponectin receptor 1 multiple interactions ISO [Dietary Fats co-treated with Aurothioglucose] results in decreased expression of ADIPOR1 protein CTD PMID:21382165 NCBI chr13:45,859,461...45,879,248
Ensembl chr13:45,859,533...45,879,241
JBrowse link
G Adipor2 adiponectin receptor 2 multiple interactions ISO [Dietary Fats co-treated with Aurothioglucose] results in decreased expression of ADIPOR2 protein CTD PMID:21382165 NCBI chr 4:152,524,604...152,588,848
Ensembl chr 4:152,524,623...152,559,355
JBrowse link
G As3mt arsenite methyltransferase multiple interactions EXP Aurothioglucose inhibits the reaction [AS3MT protein results in increased methylation of Arsenic] CTD PMID:15025511 NCBI chr 1:245,595,939...245,628,921
Ensembl chr 1:245,596,108...245,627,872
JBrowse link
G Chuk component of inhibitor of nuclear factor kappa B kinase complex multiple interactions ISO Aurothioglucose inhibits the reaction [Lipopolysaccharides results in increased activity of CHUK protein] CTD PMID:10820281 NCBI chr 1:242,959,539...242,995,066
Ensembl chr 1:242,959,760...242,995,065
JBrowse link
G Fas Fas cell surface death receptor multiple interactions ISO [Dietary Fats co-treated with Aurothioglucose] results in decreased expression of FAS protein CTD PMID:21382165 NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
JBrowse link
G Gstp1 glutathione S-transferase pi 1 multiple interactions ISO Aurothioglucose inhibits the reaction [GSTP1 protein results in increased metabolism of 1-chloro-2,4-dinitrobenzene-glutathione conjugate] CTD PMID:23769903 NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226
JBrowse link
G Il1b interleukin 1 beta multiple interactions ISO [Dexamethasone co-treated with Aurothioglucose] inhibits the reaction [IL1B protein results in increased expression of TYMP mRNA] CTD PMID:15990992 NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
JBrowse link
G Lep leptin multiple interactions
increases expression
ISO [Sodium Glutamate co-treated with Aurothioglucose] results in increased expression of LEP mRNA; [Sodium Glutamate co-treated with Aurothioglucose] results in increased expression of LEP protein
Aurothioglucose results in increased expression of LEP mRNA; Aurothioglucose results in increased expression of LEP protein
CTD PMID:7489415 PMID:9794456 PMID:15809509 NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262
JBrowse link
G Npy neuropeptide Y decreases expression ISO Aurothioglucose results in decreased expression of NPY mRNA CTD PMID:9794456 NCBI chr 4:78,881,294...78,888,495
Ensembl chr 4:78,881,264...78,888,495
JBrowse link
G Pomc proopiomelanocortin decreases expression ISO Aurothioglucose results in decreased expression of POMC mRNA CTD PMID:9794456 NCBI chr 6:26,939,844...26,945,666
Ensembl chr 6:26,939,837...26,945,664
JBrowse link
G Pparg peroxisome proliferator-activated receptor gamma multiple interactions ISO [Dietary Fats co-treated with Aurothioglucose] results in decreased expression of PPARG protein CTD PMID:21382165 NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
JBrowse link
G Retn resistin decreases expression ISO Aurothioglucose results in decreased expression of RETN CTD PMID:15809509 NCBI chr12:1,710,881...1,712,621
Ensembl chr12:1,710,881...1,712,620
JBrowse link
G Tgfb1 transforming growth factor, beta 1 multiple interactions ISO [Dietary Fats co-treated with Aurothioglucose] results in increased expression of TGFB1 protein CTD PMID:21382165 NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
JBrowse link
G Timp1 TIMP metallopeptidase inhibitor 1 multiple interactions ISO [Dietary Fats co-treated with Aurothioglucose] results in increased expression of TIMP1 protein CTD PMID:21382165 NCBI chr  X:1,212,969...1,217,714
Ensembl chr  X:1,212,972...1,217,664
JBrowse link
G Txnrd1 thioredoxin reductase 1 decreases activity ISO Aurothioglucose results in decreased activity of TXNRD1 protein CTD PMID:21172426 NCBI chr 7:20,830,042...20,914,990
Ensembl chr 7:20,830,045...20,907,863
JBrowse link
G Txnrd2 thioredoxin reductase 2 decreases activity ISO Aurothioglucose results in decreased activity of TXNRD2 protein CTD PMID:21172426 NCBI chr11:82,519,996...82,568,156
Ensembl chr11:82,519,999...82,568,156
JBrowse link
G Tymp thymidine phosphorylase multiple interactions ISO [Dexamethasone co-treated with Aurothioglucose] inhibits the reaction [IL1B protein results in increased expression of TYMP mRNA] CTD PMID:15990992 NCBI chr 7:120,438,768...120,444,088
Ensembl chr 7:120,438,770...120,443,874
Ensembl chr 7:120,438,770...120,443,874
JBrowse link
bafilomycin A1 term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Agt angiotensinogen multiple interactions EXP bafilomycin A1 inhibits the reaction [AGT protein affects the localization of Calcium] CTD PMID:21613610 NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
JBrowse link
G Aim2 absent in melanoma 2 multiple interactions ISO [bafilomycin A1 co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in increased expression of AIM2 protein CTD PMID:32645460 NCBI chr13:85,865,206...85,906,996
Ensembl chr13:85,866,284...85,906,975
JBrowse link
G Akt1s1 AKT1 substrate 1 multiple interactions EXP bafilomycin A1 inhibits the reaction [EGF protein results in increased phosphorylation of AKT1S1 protein] CTD PMID:22689575 NCBI chr 1:95,333,186...95,339,678
Ensembl chr 1:95,332,898...95,339,677
JBrowse link
G Alb albumin decreases uptake ISO bafilomycin A1 results in decreased uptake of ALB protein CTD PMID:16313995 NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
JBrowse link
G Apaf1 apoptotic peptidase activating factor 1 increases expression ISO bafilomycin A1 results in increased expression of APAF1 protein CTD PMID:28483490 NCBI chr 7:25,494,143...25,579,540
Ensembl chr 7:25,494,609...25,579,540
JBrowse link
G Appl1 adaptor protein, phosphotyrosine interacting with PH domain and leucine zipper 1 multiple interactions ISO bafilomycin A1 promotes the reaction [Lipopolysaccharides results in increased degradation of APPL1 protein]; bafilomycin A1 promotes the reaction [Poly I-C results in increased degradation of APPL1 protein] CTD PMID:25780039 NCBI chr16:2,118,503...2,166,741
Ensembl chr16:2,121,255...2,166,692
JBrowse link
G Asic1 acid sensing ion channel subunit 1 multiple interactions ISO bafilomycin A1 inhibits the reaction [Freund's Adjuvant results in increased expression of ASIC1 mRNA] CTD PMID:16769263 NCBI chr 7:130,798,317...130,828,535
Ensembl chr 7:130,799,917...130,828,541
JBrowse link
G Atg5 autophagy related 5 multiple interactions ISO ATG5 protein affects the reaction [bafilomycin A1 promotes the reaction [gossypol acetic acid results in increased expression of MAP1LC3B protein modified form]] CTD PMID:29938581 NCBI chr20:47,798,222...47,889,216
Ensembl chr20:47,798,290...47,889,209
JBrowse link
G Bax BCL2 associated X, apoptosis regulator multiple interactions ISO bafilomycin A1 inhibits the reaction [Hydroxychloroquine results in increased activity of BAX protein] CTD PMID:12813466 NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
JBrowse link
G Bcl2 BCL2, apoptosis regulator decreases expression ISO bafilomycin A1 results in decreased expression of BCL2 mRNA CTD PMID:31310755 NCBI chr13:22,689,783...22,853,920 JBrowse link
G Becn1 beclin 1 multiple interactions
increases expression
ISO
EXP
bafilomycin A1 inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of BECN1 protein]
[Swainsonine co-treated with bafilomycin A1] results in increased expression of BECN1 protein; bafilomycin A1 promotes the reaction [[lead acetate results in increased abundance of Lead] which results in increased expression of BECN1 protein]
bafilomycin A1 results in increased expression of BECN1 protein
CTD PMID:32645460 PMID:33186601 PMID:33242459 NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742
JBrowse link
G Bglap bone gamma-carboxyglutamate protein multiple interactions ISO bafilomycin A1 inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of BGLAP mRNA] CTD PMID:23111315 NCBI chr 2:173,838,518...173,839,495
Ensembl chr 2:173,838,518...173,839,495
JBrowse link
G Bid BH3 interacting domain death agonist multiple interactions
increases cleavage
increases expression
EXP
ISO
bafilomycin A1 inhibits the reaction [manganese chloride results in increased expression of BID protein modified form]; bafilomycin A1 inhibits the reaction [manganese chloride results in increased expression of BID protein]
vistusertib affects the reaction [bafilomycin A1 results in increased cleavage of BID protein]
bafilomycin A1 results in increased expression of BID protein modified form
CTD PMID:26853465 PMID:28378122 NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720
JBrowse link
G Bnip3 BCL2 interacting protein 3 increases expression
multiple interactions
ISO bafilomycin A1 results in increased expression of BNIP3 mRNA; bafilomycin A1 results in increased expression of BNIP3 protein
BNIP3 mutant form promotes the reaction [bafilomycin A1 results in increased cleavage of PARP1 protein]; capivasertib affects the reaction [bafilomycin A1 results in increased expression of BNIP3 protein]; Erlotinib Hydrochloride inhibits the reaction [bafilomycin A1 results in increased expression of BNIP3 protein]; Gefitinib inhibits the reaction [bafilomycin A1 results in increased expression of BNIP3 protein]; HIF1A mutant form inhibits the reaction [bafilomycin A1 results in increased expression of BNIP3 mRNA]; Lapatinib inhibits the reaction [bafilomycin A1 results in increased expression of BNIP3 mRNA]; vistusertib inhibits the reaction [bafilomycin A1 results in increased expression of BNIP3 protein]
CTD PMID:25981168 PMID:26853465 NCBI chr 1:193,708,164...193,725,348
Ensembl chr 1:193,708,167...193,725,359
JBrowse link
G C1qtnf9 C1q and TNF related 9 multiple interactions EXP bafilomycin A1 promotes the reaction [C1QTNF9 protein results in increased expression of MAP1LC3B protein modified form] CTD PMID:32278738 NCBI chr15:34,907,791...34,922,985
Ensembl chr15:34,911,286...34,922,980
JBrowse link
G Casp3 caspase 3 decreases activity
increases cleavage
multiple interactions
increases activity
ISO
EXP
bafilomycin A1 results in decreased activity of CASP3 protein
bafilomycin A1 results in increased cleavage of CASP3 protein
bafilomycin A1 inhibits the reaction [Cadmium results in increased cleavage of CASP3 protein]
bafilomycin A1 results in increased activity of CASP3 protein
[Swainsonine co-treated with bafilomycin A1] results in increased cleavage of CASP3 protein; bafilomycin A1 inhibits the reaction [manganese chloride results in increased cleavage of CASP3 protein]; bafilomycin A1 promotes the reaction [Hydrogen Peroxide results in increased expression of CASP3 protein modified form]
[bafilomycin A1 co-treated with Cannabidiol] results in increased cleavage of CASP3 protein; [bafilomycin A1 co-treated with cobaltous chloride co-treated with TP53 gene mutant form] results in increased activity of CASP3 protein; [bafilomycin A1 co-treated with methanandamide] results in increased cleavage of CASP3 protein; [Cannabidiol co-treated with bafilomycin A1] results in increased cleavage of CASP3 protein; bafilomycin A1 inhibits the reaction [Soot analog results in increased expression of CASP3 protein]; bafilomycin A1 inhibits the reaction [tetrandrine results in increased cleavage of CASP3 protein]; bafilomycin A1 promotes the reaction [Atorvastatin results in increased cleavage of CASP3 protein]; bafilomycin A1 promotes the reaction [brazilin results in increased activity of CASP3 protein]; bafilomycin A1 promotes the reaction [fosbretabulin results in increased cleavage of CASP3 protein]; tin protoporphyrin IX inhibits the reaction [[bafilomycin A1 co-treated with Cannabidiol] results in increased cleavage of CASP3 protein]; tin protoporphyrin IX inhibits the reaction [[bafilomycin A1 co-treated with methanandamide] results in increased cleavage of CASP3 protein]; vistusertib affects the reaction [bafilomycin A1 results in increased cleavage of CASP3 protein]
CTD PMID:20876807 PMID:23380477 PMID:24321340 PMID:24889822 PMID:25266202 More... NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
JBrowse link
G Casp4 caspase 4 increases activity ISO bafilomycin A1 results in increased activity of CASP4 protein CTD PMID:20371669 NCBI chr 8:2,599,017...2,635,097
Ensembl chr 8:2,598,876...2,635,092
JBrowse link
G Casp7 caspase 7 increases activity
decreases activity
ISO bafilomycin A1 results in increased activity of CASP7 protein
bafilomycin A1 results in decreased activity of CASP7 protein
CTD PMID:20371669 PMID:25981168 NCBI chr 1:255,437,195...255,476,737
Ensembl chr 1:255,437,172...255,476,729
JBrowse link
G Casp8 caspase 8 multiple interactions EXP
ISO
bafilomycin A1 inhibits the reaction [manganese chloride results in increased cleavage of CASP8 protein]
bafilomycin A1 inhibits the reaction [Cadmium results in increased cleavage of CASP8 protein]
CTD PMID:28378122 PMID:29111403 NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
JBrowse link
G Casp9 caspase 9 multiple interactions EXP
ISO
bafilomycin A1 inhibits the reaction [manganese chloride results in increased cleavage of CASP9 protein]
bafilomycin A1 inhibits the reaction [Soot analog results in increased expression of CASP9 protein]
CTD PMID:28378122 PMID:30240709 NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
JBrowse link
G Ccnd1 cyclin D1 multiple interactions ISO bafilomycin A1 inhibits the reaction [Dexamethasone results in decreased expression of CCND1 protein] CTD PMID:33359579 NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
JBrowse link
G Cdc25c cell division cycle 25C multiple interactions ISO bafilomycin A1 inhibits the reaction [xanthatin results in decreased stability of CDC25C protein] CTD PMID:29074359 NCBI chr18:26,335,156...26,356,199
Ensembl chr18:26,335,834...26,356,185
JBrowse link
G Ctsb cathepsin B multiple interactions ISO bafilomycin A1 inhibits the reaction [[cobaltous chloride co-treated with TP53 gene mutant form] results in increased activity of CTSB protein]; bafilomycin A1 inhibits the reaction [Hydroxychloroquine affects the localization of CTSB protein] CTD PMID:12813466 PMID:23380477 NCBI chr15:37,389,636...37,410,508
Ensembl chr15:37,389,629...37,410,500
JBrowse link
G Cxcl10 C-X-C motif chemokine ligand 10 multiple interactions ISO bafilomycin A1 inhibits the reaction [CpG ODN 2216 results in increased expression of CXCL10 protein]; bafilomycin A1 inhibits the reaction [gardiquimod results in increased expression of CXCL10 protein]; bafilomycin A1 inhibits the reaction [Poly I-C results in increased expression of CXCL10 protein] CTD PMID:26682054 NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975
JBrowse link
G Ddit4 DNA-damage-inducible transcript 4 increases expression
multiple interactions
EXP bafilomycin A1 results in increased expression of DDIT4 protein
[EGF protein co-treated with bafilomycin A1] results in increased expression of DDIT4 protein
CTD PMID:22689575 NCBI chr20:27,891,989...27,894,088
Ensembl chr20:27,891,998...27,894,105
JBrowse link
G Egf epidermal growth factor multiple interactions EXP [bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Arginine; [bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Asparagine; [bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Isoleucine; [bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Leucine; [bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Lysine; [bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Methionine; [bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Ornithine; [bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Phenylalanine; [bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Tyrosine; [bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Valine; [bafilomycin A1 co-treated with EGF protein] results in increased abundance of Aspartic Acid; [bafilomycin A1 co-treated with EGF protein] results in increased abundance of Taurine; [EGF protein co-treated with bafilomycin A1] results in increased expression of DDIT4 protein; bafilomycin A1 inhibits the reaction [EGF protein results in increased activity of and results in increased phosphorylation of RPS6KB1 protein]; bafilomycin A1 inhibits the reaction [EGF protein results in increased phosphorylation of AKT1S1 protein]; bafilomycin A1 inhibits the reaction [EGF protein results in increased phosphorylation of EIF4EBP1 protein]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Arginine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Asparagine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Isoleucine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Leucine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Lysine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Methionine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Ornithine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Phenylalanine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Tyrosine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Valine] CTD PMID:22689575 NCBI chr 2:218,219,408...218,302,370
Ensembl chr 2:218,219,415...218,302,064
JBrowse link
G Egfr epidermal growth factor receptor multiple interactions ISO bafilomycin A1 inhibits the reaction [Arsenic Trioxide results in decreased expression of EGFR protein] CTD PMID:30237564 NCBI chr14:91,176,931...91,349,722
Ensembl chr14:91,177,067...91,344,382
JBrowse link
G Eif4ebp1 eukaryotic translation initiation factor 4E binding protein 1 multiple interactions EXP bafilomycin A1 inhibits the reaction [EGF protein results in increased phosphorylation of EIF4EBP1 protein]; bafilomycin A1 inhibits the reaction [INS protein results in increased phosphorylation of EIF4EBP1 protein] CTD PMID:22689575 NCBI chr16:64,792,595...64,805,984
Ensembl chr16:64,790,226...64,805,984
JBrowse link
G Epor erythropoietin receptor multiple interactions ISO bafilomycin A1 inhibits the reaction [Aristolochic Acids results in increased degradation of and results in decreased expression of EPOR protein] CTD PMID:26136230 NCBI chr 8:20,489,678...20,494,257
Ensembl chr 8:20,489,678...20,494,257
JBrowse link
G Faslg Fas ligand multiple interactions ISO
EXP
bafilomycin A1 inhibits the reaction [FASL protein affects the localization of Calcium]
bafilomycin A1 inhibits the reaction [manganese chloride results in increased expression of FASLG protein]
CTD PMID:20200208 PMID:28378122 NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215
JBrowse link
G Fmc1 formation of mitochondrial complex V assembly factor 1 multiple interactions ISO bafilomycin A1 inhibits the reaction [Carbonyl Cyanide m-Chlorophenyl Hydrazone results in decreased expression of FMC1 protein] CTD PMID:29371327 NCBI chr 4:67,274,104...67,282,140
Ensembl chr 4:67,274,104...67,282,140
JBrowse link
G Foxo1 forkhead box O1 multiple interactions EXP bafilomycin A1 inhibits the reaction [resveratrol inhibits the reaction [Hydrogen Peroxide results in increased acetylation of FOXO1 protein]] CTD PMID:24889822 NCBI chr 2:136,312,168...136,390,603
Ensembl chr 2:136,312,168...136,387,790
JBrowse link
G Hif1a hypoxia inducible factor 1 subunit alpha increases expression
multiple interactions
ISO bafilomycin A1 results in increased expression of HIF1A protein
HIF1A mutant form inhibits the reaction [bafilomycin A1 results in increased expression of BNIP3 mRNA]; HIF1A mutant form promotes the reaction [bafilomycin A1 results in increased cleavage of PARP1 protein]; lapatinib inhibits the reaction [bafilomycin A1 results in increased expression of HIF1A protein]
CTD PMID:25981168 NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
JBrowse link
G Hmox1 heme oxygenase 1 decreases expression
multiple interactions
ISO bafilomycin A1 results in decreased expression of HMOX1 protein
[bafilomycin A1 co-treated with methanandamide] results in increased expression of HMOX1 protein; [bafilomycin A1 co-treated with tin protoporphyrin IX] promotes the reaction [Cannabidiol results in increased expression of HMOX1 protein]; bafilomycin A1 inhibits the reaction [4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole results in increased expression of HMOX1 protein]
CTD PMID:29796178 PMID:33076330 NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
JBrowse link
G Ifng interferon gamma decreases expression ISO bafilomycin A1 results in decreased expression of IFNG mRNA CTD PMID:16932910 NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
JBrowse link
G Il1b interleukin 1 beta decreases expression
multiple interactions
ISO bafilomycin A1 results in decreased expression of IL1B mRNA
[bafilomycin A1 co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in increased expression of IL1B protein; bafilomycin A1 inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with aluminum sulfate] results in increased secretion of IL1B protein]
CTD PMID:16932910 PMID:24158569 PMID:32645460 NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
JBrowse link
G Il6 interleukin 6 increases expression ISO bafilomycin A1 results in increased expression of IL6 mRNA CTD PMID:16932910 NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
JBrowse link
G Ins2 insulin 2 multiple interactions EXP
ISO
bafilomycin A1 inhibits the reaction [INS protein results in increased phosphorylation of EIF4EBP1 protein]; bafilomycin A1 inhibits the reaction [INS protein results in increased phosphorylation of RPS6KB1 protein]
bafilomycin A1 promotes the reaction [Palmitic Acid inhibits the reaction [INS1 protein results in increased uptake of 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose]]
CTD PMID:22689575 PMID:32283200 NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775
JBrowse link
G Lrrk2 leucine-rich repeat kinase 2 increases response to substance ISO LRRK2 gene mutant form results in increased susceptibility to bafilomycin A1 CTD PMID:25017139 NCBI chr 7:122,826,712...122,987,711
Ensembl chr 7:122,826,696...122,987,703
JBrowse link
G Map1lc3a microtubule-associated protein 1 light chain 3 alpha multiple interactions
increases expression
ISO bafilomycin A1 promotes the reaction [Uranium results in increased expression of MAP1LC3A protein]
bafilomycin A1 results in increased expression of MAP1LC3A protein modified form
CTD PMID:30871063 PMID:31120128 NCBI chr 3:143,783,024...143,784,670
Ensembl chr 3:143,783,024...143,784,670
JBrowse link
G Map1lc3b microtubule-associated protein 1 light chain 3 beta multiple interactions
increases lipidation
increases expression
increases cleavage
decreases degradation
ISO
EXP
[bafilomycin A1 co-treated with Miconazole] results in increased expression of MAP1LC3B protein; [di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone co-treated with bafilomycin A1] results in increased expression of MAP1LC3B mRNA; [TNF protein co-treated with bafilomycin A1] results in increased expression of MAP1LC3B protein alternative form; Acetylcysteine inhibits the reaction [di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone promotes the reaction [bafilomycin A1 results in increased expression of MAP1LC3B protein]]; ATG5 protein affects the reaction [bafilomycin A1 promotes the reaction [gossypol acetic acid results in increased expression of MAP1LC3B protein modified form]]; bafilomycin A1 affects the reaction [Ammonium Chloride results in increased metabolism of MAP1LC3B protein]; bafilomycin A1 affects the reaction [AZD4547 affects the expression of MAP1LC3B protein modified form]; bafilomycin A1 affects the reaction [AZD8186 affects the expression of MAP1LC3B protein modified form]; bafilomycin A1 inhibits the reaction [Chloroquine results in increased lipidation of MAP1LC3B protein]; bafilomycin A1 promotes the reaction [capivasertib results in increased expression of MAP1LC3B protein modified form]; bafilomycin A1 promotes the reaction [ginsenoside Rg2 results in increased expression of MAP1LC3B protein modified form]; bafilomycin A1 promotes the reaction [gossypol acetic acid results in increased expression of MAP1LC3B protein modified form]; bafilomycin A1 promotes the reaction [metarrestin results in increased expression of MAP1LC3B protein modified form]; bafilomycin A1 promotes the reaction [Miconazole results in increased lipidation of MAP1LC3B protein]; bafilomycin A1 promotes the reaction [Resveratrol results in increased expression of MAP1LC3B protein alternative form]; bafilomycin A1 promotes the reaction [vistusertib results in increased expression of MAP1LC3B protein modified form]; di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone promotes the reaction [bafilomycin A1 results in increased expression of MAP1LC3B protein]; Resveratrol promotes the reaction [[TNF protein co-treated with bafilomycin A1] results in increased expression of MAP1LC3B protein alternative form]
bafilomycin A1 results in increased lipidation of MAP1LC3B protein
[Doxorubicin co-treated with bafilomycin A1] results in increased expression of MAP1LC3B protein; [Glycyrrhizic Acid co-treated with bafilomycin A1] results in increased lipidation of MAP1LC3B protein; bafilomycin A1 promotes the reaction [C1QTNF9 protein results in increased expression of MAP1LC3B protein modified form]
bafilomycin A1 results in increased expression of MAP1LC3B protein modified form
bafilomycin A1 promotes the reaction [Triiodothyronine results in increased lipidation of MAP1LC3B protein]; Triiodothyronine promotes the reaction [bafilomycin A1 results in increased lipidation of MAP1LC3B protein]
bafilomycin A1 results in increased cleavage of MAP1LC3B protein
bafilomycin A1 results in decreased degradation of MAP1LC3B protein modified form
bafilomycin A1 results in increased expression of MAP1LC3B protein; bafilomycin A1 results in increased expression of MAP1LC3B protein alternative form; bafilomycin A1 results in increased expression of MAP1LC3B protein modified form
CTD PMID:23880069 PMID:24145604 PMID:25301941 PMID:26459185 PMID:26853465 More... NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690
JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions
increases expression
ISO bafilomycin A1 inhibits the reaction [Capsaicin results in increased activity of MAPK1 protein]; bafilomycin A1 inhibits the reaction [Iron Compounds results in increased expression of MAPK1 protein modified form]; bafilomycin A1 promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased phosphorylation of MAPK1 protein]
bafilomycin A1 results in increased expression of MAPK1 protein modified form
CTD PMID:20371669 PMID:28483490 PMID:32645460 NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions
increases expression
ISO bafilomycin A1 inhibits the reaction [Capsaicin results in increased activity of MAPK3 protein]; bafilomycin A1 inhibits the reaction [Iron Compounds results in increased expression of MAPK3 protein modified form]; bafilomycin A1 promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased phosphorylation of MAPK3 protein]
bafilomycin A1 results in increased expression of MAPK3 protein modified form
CTD PMID:20371669 PMID:28483490 PMID:32645460 NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
JBrowse link
G Mapk8 mitogen-activated protein kinase 8 increases phosphorylation ISO bafilomycin A1 results in increased phosphorylation of MAPK8 protein CTD PMID:31310755 NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
JBrowse link
G Mtor mechanistic target of rapamycin kinase decreases phosphorylation ISO bafilomycin A1 results in decreased phosphorylation of MTOR protein CTD PMID:31310755 NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
JBrowse link
G Ndrg1 N-myc downstream regulated 1 multiple interactions ISO NDRG1 protein results in decreased susceptibility to [di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone co-treated with bafilomycin A1] CTD PMID:24532803 NCBI chr 7:98,684,487...98,725,869
Ensembl chr 7:98,684,487...98,725,880
JBrowse link
G Nfe2l2 nuclear factor, erythroid 2-like 2 multiple interactions
increases expression
ISO bafilomycin A1 promotes the reaction [[Particulate Matter co-treated with Vitamin D] results in increased expression of NFE2L2 protein]; bafilomycin A1 promotes the reaction [[Silicon Dioxide co-treated with Vitamin D] results in increased expression of NFE2L2 protein]; bafilomycin A1 promotes the reaction [Particulate Matter results in increased expression of NFE2L2 protein]; bafilomycin A1 promotes the reaction [Silicon Dioxide results in increased expression of NFE2L2 protein]
bafilomycin A1 results in increased expression of NFE2L2 protein
CTD PMID:30698894 NCBI chr 3:60,594,239...60,621,785
Ensembl chr 3:60,594,242...60,621,737
JBrowse link
G Nlrp3 NLR family, pyrin domain containing 3 multiple interactions
increases expression
ISO bafilomycin A1 inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in decreased expression of NLRP3 protein]
bafilomycin A1 results in increased expression of NLRP3 protein
CTD PMID:32645460 NCBI chr10:44,326,770...44,353,814
Ensembl chr10:44,328,566...44,352,811
JBrowse link
G Nr5a1 nuclear receptor subfamily 5, group A, member 1 decreases expression ISO bafilomycin A1 results in decreased expression of NR5A1 protein CTD PMID:29524503 NCBI chr 3:22,464,786...22,486,328
Ensembl chr 3:22,465,502...22,486,328
JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions
increases cleavage
increases expression
ISO bafilomycin A1 promotes the reaction [Atorvastatin results in increased cleavage of PARP1 protein]; bafilomycin A1 promotes the reaction [brazilin results in increased expression of PARP1 protein modified form]; bafilomycin A1 promotes the reaction [Flavanones results in increased cleavage of PARP1 protein]; bafilomycin A1 promotes the reaction [fosbretabulin results in increased cleavage of PARP1 protein]; BNIP3 mutant form promotes the reaction [bafilomycin A1 results in increased cleavage of PARP1 protein]; HIF1A mutant form promotes the reaction [bafilomycin A1 results in increased cleavage of PARP1 protein]
bafilomycin A1 inhibits the reaction [Cadmium results in increased cleavage of PARP1 protein]
bafilomycin A1 results in increased expression of PARP1 protein modified form
CTD PMID:20876807 PMID:21616090 PMID:24321340 PMID:25981168 PMID:28063998 More... NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
JBrowse link
G Pcna proliferating cell nuclear antigen multiple interactions ISO bafilomycin A1 inhibits the reaction [Dexamethasone results in decreased expression of PCNA mRNA] CTD PMID:33359579 NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995
JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit multiple interactions ISO bafilomycin A1 affects the localization of and results in increased activity of RELA protein CTD PMID:10339586 NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
JBrowse link
G Rps6kb1 ribosomal protein S6 kinase B1 decreases phosphorylation
multiple interactions
ISO
EXP
bafilomycin A1 results in decreased phosphorylation of RPS6KB1 protein
bafilomycin A1 inhibits the reaction [EGF protein results in increased activity of and results in increased phosphorylation of RPS6KB1 protein]; bafilomycin A1 inhibits the reaction [INS protein results in increased phosphorylation of RPS6KB1 protein]
CTD PMID:22689575 PMID:31310755 NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908
JBrowse link
G Runx2 RUNX family transcription factor 2 multiple interactions ISO bafilomycin A1 inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 mRNA] CTD PMID:23111315 NCBI chr 9:16,167,504...16,492,826
Ensembl chr 9:16,167,482...16,492,167
JBrowse link
G Sirt1 sirtuin 1 multiple interactions EXP bafilomycin A1 inhibits the reaction [resveratrol inhibits the reaction [Hydrogen Peroxide results in decreased expression of SIRT1 protein]] CTD PMID:24889822 NCBI chr20:25,307,143...25,329,260
Ensembl chr20:25,306,917...25,329,260
JBrowse link
G Slc17a7 solute carrier family 17 member 7 multiple interactions EXP bafilomycin A1 inhibits the reaction [SLC17A7 protein results in increased uptake of Excitatory Amino Acid Agents]; bafilomycin A1 inhibits the reaction [SLC17A7 protein results in increased uptake of Zinc]; bafilomycin A1 inhibits the reaction [SLC30A3 protein promotes the reaction [SLC17A7 protein results in increased uptake of Zinc]] CTD PMID:15860731 NCBI chr 1:95,649,709...95,661,591
Ensembl chr 1:95,649,745...95,661,588
JBrowse link
G Slc30a3 solute carrier family 30 member 3 multiple interactions EXP bafilomycin A1 inhibits the reaction [SLC30A3 protein promotes the reaction [SLC17A7 protein results in increased uptake of Zinc]] CTD PMID:15860731 NCBI chr 6:25,264,310...25,284,720
Ensembl chr 6:25,275,528...25,284,720
JBrowse link
G Snai1 snail family transcriptional repressor 1 multiple interactions
increases expression
ISO bafilomycin A1 promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of SNAI1 protein]
bafilomycin A1 results in increased expression of SNAI1 protein
CTD PMID:32645460 NCBI chr 3:156,248,479...156,252,969
Ensembl chr 3:156,248,485...156,252,969
JBrowse link
G Snca synuclein alpha multiple interactions
increases expression
ISO [bafilomycin A1 co-treated with Rotenone] results in increased expression of SNCA protein
bafilomycin A1 results in increased expression of SNCA protein
CTD PMID:26031332 NCBI chr 4:89,696,420...89,797,240
Ensembl chr 4:89,696,420...89,796,262
JBrowse link
G Sort1 sortilin 1 decreases expression ISO bafilomycin A1 results in decreased expression of SORT1 protein CTD PMID:25805502 NCBI chr 2:195,924,033...196,002,354
Ensembl chr 2:195,924,099...196,002,354
JBrowse link
G Sqstm1 sequestosome 1 increases expression
multiple interactions
ISO
EXP
bafilomycin A1 results in increased expression of SQSTM1 protein
bafilomycin A1 promotes the reaction [Hydrogen Peroxide results in increased expression of SQSTM1 protein]
[Resveratrol co-treated with bafilomycin A1] results in increased expression of SQSTM1 protein; [Silicon Dioxide co-treated with bafilomycin A1] results in increased expression of SQSTM1 protein; [Silicon Dioxide co-treated with Vitamin D co-treated with bafilomycin A1] results in increased expression of SQSTM1 protein; [TNF protein co-treated with bafilomycin A1] results in increased expression of SQSTM1 protein; [Vitamin D co-treated with bafilomycin A1] results in increased expression of SQSTM1 protein; bafilomycin A1 inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in decreased expression of SQSTM1 protein]; bafilomycin A1 inhibits the reaction [dactolisib results in decreased expression of SQSTM1 protein]; bafilomycin A1 inhibits the reaction [Dexamethasone results in decreased expression of SQSTM1 protein]; bafilomycin A1 inhibits the reaction [Resveratrol results in increased degradation of SQSTM1 protein]; bafilomycin A1 inhibits the reaction [Sorafenib results in decreased expression of SQSTM1 protein]; bafilomycin A1 promotes the reaction [ginsenoside Rg2 results in decreased expression of SQSTM1 protein]; bafilomycin A1 promotes the reaction [metarrestin results in decreased expression of SQSTM1 protein]; bafilomycin A1 promotes the reaction [Miconazole results in increased expression of SQSTM1 protein]; bafilomycin A1 promotes the reaction [N-Methyl-3,4-methylenedioxyamphetamine results in increased expression of SQSTM1 protein]; Fingolimod Hydrochloride affects the reaction [bafilomycin A1 results in increased expression of SQSTM1 protein]; sodium arsenite promotes the reaction [bafilomycin A1 results in increased expression of SQSTM1 protein]
[bafilomycin A1 co-treated with Rotenone] results in increased expression of SQSTM1 protein; bafilomycin A1 inhibits the reaction [Resveratrol inhibits the reaction [Streptozocin results in increased expression of SQSTM1 protein]]; bafilomycin A1 inhibits the reaction [Sirolimus results in decreased expression of SQSTM1 protein]; Streptozocin promotes the reaction [bafilomycin A1 results in increased expression of SQSTM1 protein]
CTD PMID:21778691 PMID:21858812 PMID:23151917 PMID:24145604 PMID:24238063 More... NCBI chr10:34,525,517...34,536,685
Ensembl chr10:34,525,519...34,536,673
JBrowse link
G Tbk1 TANK-binding kinase 1 multiple interactions ISO bafilomycin A1 promotes the reaction [Lipopolysaccharides results in increased phosphorylation of TBK1 protein]; bafilomycin A1 promotes the reaction [Poly I-C results in increased phosphorylation of TBK1 protein] CTD PMID:25780039 NCBI chr 7:57,077,830...57,110,868
Ensembl chr 7:57,077,830...57,110,892
JBrowse link
G Tlr8 toll-like receptor 8 multiple interactions ISO bafilomycin A1 inhibits the reaction [resiquimod results in increased activity of TLR8 protein] CTD PMID:21398612 NCBI chr  X:27,091,780...27,116,092
Ensembl chr  X:27,091,778...27,116,549
JBrowse link
G Tnf tumor necrosis factor increases expression
multiple interactions
ISO bafilomycin A1 results in increased expression of TNF mRNA
[TNF protein co-treated with bafilomycin A1] results in increased expression of MAP1LC3B protein alternative form; [TNF protein co-treated with bafilomycin A1] results in increased expression of SQSTM1 protein; resveratrol promotes the reaction [[TNF protein co-treated with bafilomycin A1] results in increased expression of MAP1LC3B protein alternative form]
CTD PMID:16932910 PMID:24145604 NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
JBrowse link
G Tomm20 translocase of outer mitochondrial membrane 20 increases expression
multiple interactions
ISO bafilomycin A1 results in increased expression of TOMM20 protein
Triiodothyronine promotes the reaction [bafilomycin A1 results in increased expression of TOMM20 protein]
CTD PMID:30209975 NCBI chr19:54,925,197...54,935,188
Ensembl chr19:54,923,402...54,935,198
JBrowse link
G Tp53 tumor protein p53 multiple interactions ISO [bafilomycin A1 co-treated with cobaltous chloride co-treated with TP53 gene mutant form] results in increased activity of CASP3 protein; bafilomycin A1 inhibits the reaction [[cobaltous chloride co-treated with TP53 gene mutant form] results in increased activity of CTSB protein] CTD PMID:23380477 NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
JBrowse link
G Ulk1 unc-51 like autophagy activating kinase 1 multiple interactions EXP bafilomycin A1 affects the reaction [N-(1,3-benzodioxol-5-ylmethyl)-2,6-dichlorobenzamide affects the reaction [Glucose affects the phosphorylation of ULK1 protein]] CTD PMID:29128638 NCBI chr12:45,851,710...45,877,966
Ensembl chr12:45,851,710...45,877,966
JBrowse link
G Vdac1 voltage-dependent anion channel 1 multiple interactions
increases expression
ISO Triiodothyronine promotes the reaction [bafilomycin A1 results in increased expression of VDAC1 protein] CTD PMID:30209975 NCBI chr10:36,532,306...36,559,642
Ensembl chr10:36,532,244...36,559,640
JBrowse link
G Vdr vitamin D receptor multiple interactions ISO [bafilomycin A1 co-treated with Vitamin D] results in increased expression of VDR protein; [Silicon Dioxide co-treated with Vitamin D co-treated with bafilomycin A1] results in increased expression of VDR protein CTD PMID:30698894 NCBI chr 7:128,987,981...129,037,677
Ensembl chr 7:128,987,981...129,037,677
JBrowse link
G Vim vimentin multiple interactions
increases expression
ISO bafilomycin A1 promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of VIM protein]
bafilomycin A1 results in increased expression of VIM protein
CTD PMID:32645460 NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187
JBrowse link
Epomediol term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Cyp7a1 cytochrome P450 family 7 subfamily A member 1 increases activity
increases expression
EXP epomediol results in increased activity of CYP7A1 protein
epomediol results in increased expression of CYP7A1 mRNA
CTD PMID:10961725 PMID:11473529 NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688
JBrowse link
G Gclm glutamate cysteine ligase, modifier subunit multiple interactions EXP [Ethinyl Estradiol co-treated with epomediol] results in increased activity of GCLM protein CTD PMID:12071332 NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535
JBrowse link
G Ggt1 gamma-glutamyltransferase 1 multiple interactions EXP [Ethinyl Estradiol co-treated with epomediol] results in increased activity of GGT1 protein CTD PMID:12071332 NCBI chr20:13,074,695...13,104,095
Ensembl chr20:13,074,700...13,108,442
JBrowse link
G Hmgcr 3-hydroxy-3-methylglutaryl-CoA reductase increases activity EXP epomediol results in increased activity of HMGCR protein CTD PMID:10961725 PMID:11473529 NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703
JBrowse link
Heptachlor epoxide term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abca1 ATP binding cassette subfamily A member 1 decreases expression ISO Heptachlor Epoxide results in decreased expression of ABCA1 mRNA CTD PMID:25270620 NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170
JBrowse link
G Abcc2 ATP binding cassette subfamily C member 2 increases expression ISO Heptachlor Epoxide results in increased expression of ABCC2 mRNA CTD PMID:25270620 NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
JBrowse link
G Abcg1 ATP binding cassette subfamily G member 1 decreases expression ISO Heptachlor Epoxide results in decreased expression of ABCG1 mRNA CTD PMID:25270620 NCBI chr20:9,126,687...9,182,948
Ensembl chr20:9,126,687...9,182,948
JBrowse link
G Abhd17c abhydrolase domain containing 17C, depalmitoylase decreases expression ISO Heptachlor Epoxide results in decreased expression of ABHD17C mRNA CTD PMID:25270620 NCBI chr 1:138,084,632...138,125,595
Ensembl chr 1:138,084,634...138,125,595
JBrowse link
G Acp5 acid phosphatase 5, tartrate resistant increases expression ISO Heptachlor Epoxide results in increased expression of ACP5 mRNA CTD PMID:25270620 NCBI chr 8:20,663,984...20,670,604
Ensembl chr 8:20,663,985...20,667,929
JBrowse link
G Adgre5 adhesion G protein-coupled receptor E5 increases expression ISO Heptachlor Epoxide results in increased expression of ADGRE5 mRNA CTD PMID:25270620 NCBI chr19:24,397,972...24,418,648
Ensembl chr19:24,398,689...24,418,638
JBrowse link
G Agtr1a angiotensin II receptor, type 1a decreases expression ISO Heptachlor Epoxide results in decreased expression of AGTR1A mRNA CTD PMID:25270620 NCBI chr17:34,173,446...34,226,892
Ensembl chr17:34,174,429...34,226,946
JBrowse link
G Ammecr1l AMMECR1 like increases expression ISO Heptachlor Epoxide results in increased expression of AMMECR1L mRNA CTD PMID:25270620 NCBI chr18:23,386,114...23,411,177
Ensembl chr18:23,386,903...23,410,920
JBrowse link
G Ankrd44 ankyrin repeat domain 44 increases expression ISO Heptachlor Epoxide results in increased expression of ANKRD44 mRNA CTD PMID:25270620 NCBI chr 9:56,126,746...56,427,661
Ensembl chr 9:56,126,747...56,427,508
JBrowse link
G Aplp1 amyloid beta precursor like protein 1 increases expression ISO Heptachlor Epoxide results in increased expression of APLP1 mRNA CTD PMID:25270620 NCBI chr 1:85,696,880...85,707,215
Ensembl chr 1:85,696,882...85,707,155
JBrowse link
G Ar androgen receptor multiple interactions ISO Dihydrotestosterone inhibits the reaction [Heptachlor Epoxide results in increased activity of AR protein] CTD PMID:15064155 NCBI chr  X:63,104,771...63,273,934
Ensembl chr  X:63,104,771...63,273,925
JBrowse link
G Atl3 atlastin GTPase 3 decreases expression ISO Heptachlor Epoxide results in decreased expression of ATL3 mRNA CTD PMID:25270620 NCBI chr 1:204,680,958...204,727,360
Ensembl chr 1:204,680,968...204,723,354
JBrowse link
G Atp9a ATPase phospholipid transporting 9A (putative) decreases expression ISO Heptachlor Epoxide results in decreased expression of ATP9A mRNA CTD PMID:25270620 NCBI chr 3:157,360,354...157,467,628
Ensembl chr 3:157,360,359...157,467,818
JBrowse link
G Bhlhe40 basic helix-loop-helix family, member e40 increases expression ISO Heptachlor Epoxide results in increased expression of BHLHE40 mRNA CTD PMID:25270620 NCBI chr 4:141,618,453...141,624,154
Ensembl chr 4:141,618,476...141,624,774
JBrowse link
G Camk2n1 calcium/calmodulin-dependent protein kinase II inhibitor 1 increases expression ISO Heptachlor Epoxide results in increased expression of CAMK2N1 mRNA CTD PMID:25270620 NCBI chr 5:150,674,819...150,676,600
Ensembl chr 5:150,673,507...150,676,600
JBrowse link
G Cnot7 CCR4-NOT transcription complex, subunit 7 increases expression ISO Heptachlor Epoxide results in increased expression of CNOT7 mRNA CTD PMID:25270620 NCBI chr16:51,775,416...51,794,581
Ensembl chr16:51,775,412...51,794,576
JBrowse link
G Cpt1a carnitine palmitoyltransferase 1A decreases expression ISO Heptachlor Epoxide results in decreased expression of CPT1A mRNA CTD PMID:25270620 NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055
JBrowse link
G Cyp1a1 cytochrome P450, family 1, subfamily a, polypeptide 1 decreases activity ISO Heptachlor Epoxide results in decreased activity of CYP1A1 protein CTD PMID:15620088 NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
JBrowse link
G Cyp26a1 cytochrome P450, family 26, subfamily a, polypeptide 1 increases expression ISO Heptachlor Epoxide results in increased expression of CYP26A1 mRNA CTD PMID:25270620 NCBI chr 1:235,471,368...235,475,204
Ensembl chr 1:235,471,298...235,475,204
JBrowse link
G Cyp2c24 cytochrome P450, family 2, subfamily c, polypeptide 24 increases expression ISO Heptachlor Epoxide results in increased expression of CYP2C55 mRNA CTD PMID:25270620 NCBI chr 1:236,873,967...236,936,238
Ensembl chr 1:236,873,967...236,936,238
JBrowse link
G Cyp2c79 cytochrome P450, family 2, subfamily c, polypeptide 79 increases expression ISO Heptachlor Epoxide results in increased expression of CYP2C29 mRNA CTD PMID:25270620
G Dpp4 dipeptidylpeptidase 4 increases expression ISO Heptachlor Epoxide results in increased expression of DPP4 mRNA CTD PMID:25270620 NCBI chr 3:46,962,243...47,043,870
Ensembl chr 3:46,962,243...47,043,901
JBrowse link
G Dppa3 developmental pluripotency-associated 3 decreases expression ISO Heptachlor Epoxide results in decreased expression of DPPA3 mRNA CTD PMID:25270620 NCBI chr 4:155,851,461...155,854,845
Ensembl chr 4:155,815,296...155,854,861
JBrowse link
G Ecscr endothelial cell surface expressed chemotaxis and apoptosis regulator decreases expression ISO Heptachlor Epoxide results in decreased expression of ECSCR mRNA CTD PMID:25270620 NCBI chr18:27,309,711...27,319,106
Ensembl chr18:27,309,718...27,319,032
JBrowse link
G Efna1 ephrin A1 increases expression ISO Heptachlor Epoxide results in increased expression of EFNA1 mRNA CTD PMID:25270620 NCBI chr 2:174,681,676...174,690,306
Ensembl chr 2:174,681,682...174,690,866
JBrowse link
G Elovl6 ELOVL fatty acid elongase 6 increases expression ISO Heptachlor Epoxide results in increased expression of ELOVL6 mRNA CTD PMID:25270620 NCBI chr 2:218,063,682...218,174,767
Ensembl chr 2:218,063,804...218,171,186
JBrowse link
G Ephb4 EPH receptor B4 decreases expression ISO Heptachlor Epoxide results in decreased expression of EPHB4 mRNA CTD PMID:25270620 NCBI chr12:19,326,411...19,351,667
Ensembl chr12:19,326,427...19,351,314
JBrowse link
G Ephx1 epoxide hydrolase 1 multiple interactions ISO Heptachlor Epoxide promotes the reaction [EPHX1 protein results in increased metabolism of stilbene oxide] CTD PMID:2043152 NCBI chr13:92,714,315...92,744,124
Ensembl chr13:92,714,315...92,790,235
JBrowse link
G Ephx2 epoxide hydrolase 2 multiple interactions ISO Heptachlor Epoxide inhibits the reaction [EPHX2 protein results in increased metabolism of stilbene oxide analog]; Heptachlor Epoxide promotes the reaction [EPHX2 protein results in increased metabolism of stilbene oxide] CTD PMID:2043152 NCBI chr15:40,289,901...40,327,632
Ensembl chr15:40,289,902...40,327,615
JBrowse link
G Erbb2 erb-b2 receptor tyrosine kinase 2 increases activity ISO Heptachlor Epoxide results in increased activity of ERBB2 protein CTD PMID:11222871 NCBI chr10:83,411,197...83,435,078
Ensembl chr10:83,411,313...83,435,078
JBrowse link
G Esr1 estrogen receptor 1 increases activity ISO Heptachlor Epoxide results in increased activity of ESR1 protein CTD PMID:15064155 NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
JBrowse link
G Esr2 estrogen receptor 2 increases activity ISO Heptachlor Epoxide results in increased activity of ESR2 protein CTD PMID:15064155 NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
JBrowse link
G Exosc8 exosome component 8 increases expression ISO Heptachlor Epoxide results in increased expression of EXOSC8 mRNA CTD PMID:25270620 NCBI chr 2:138,930,405...138,937,009
Ensembl chr 2:138,930,405...138,936,928
JBrowse link
G Faah fatty acid amide hydrolase decreases expression ISO Heptachlor Epoxide results in decreased expression of FAAH mRNA CTD PMID:25270620 NCBI chr 5:129,479,774...129,499,018 JBrowse link
G Faahl fatty-acid amide hydrolase-like decreases expression ISO Heptachlor Epoxide results in decreased expression of FAAH mRNA CTD PMID:25270620
G Fgf21 fibroblast growth factor 21 decreases expression ISO Heptachlor Epoxide results in decreased expression of FGF21 mRNA CTD PMID:25270620 NCBI chr 1:96,083,495...96,084,738
Ensembl chr 1:96,083,441...96,090,454
JBrowse link
G Fmo1 flavin containing dimethylaniline monoxygenase 1 decreases expression ISO Heptachlor Epoxide results in decreased expression of FMO1 mRNA CTD PMID:25270620 NCBI chr13:75,182,184...75,214,439
Ensembl chr13:75,182,176...75,214,647
JBrowse link
G Gabarapl2 GABA type A receptor associated protein like 2 increases expression ISO Heptachlor Epoxide results in increased expression of GABARAPL2 mRNA CTD PMID:25270620 NCBI chr19:39,910,572...39,921,408
Ensembl chr19:39,910,534...39,924,628
JBrowse link
G Gja1 gap junction protein, alpha 1 decreases phosphorylation
decreases expression
multiple interactions
EXP
ISO
Heptachlor Epoxide results in decreased phosphorylation of GJA1 protein
Heptachlor Epoxide results in decreased expression of GJA1 protein
Heptachlor Epoxide results in decreased expression of and results in decreased phosphorylation of GJA1 protein
Heptachlor Epoxide results in decreased expression of GJA1 mRNA
CTD PMID:8068183 PMID:8738476 PMID:11246134 NCBI chr20:35,756,007...35,768,481
Ensembl chr20:35,755,991...35,768,582
JBrowse link
G Gjb2 gap junction protein, beta 2 decreases expression EXP Heptachlor Epoxide results in decreased expression of GJB2 protein CTD PMID:8068183 NCBI chr15:31,260,390...31,278,222
Ensembl chr15:31,260,357...31,278,177
JBrowse link
G Gjb3 gap junction protein, beta 3 decreases expression ISO Heptachlor Epoxide results in decreased expression of GJB3 mRNA CTD PMID:25270620 NCBI chr 5:139,649,227...139,655,083
Ensembl chr 5:139,649,195...139,654,980
JBrowse link
G Gsr glutathione-disulfide reductase affects activity ISO Heptachlor Epoxide affects the activity of GSR protein CTD PMID:15620088 NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
JBrowse link
G Hagh hydroxyacyl glutathione hydrolase increases expression ISO Heptachlor Epoxide results in increased expression of HAGH mRNA CTD PMID:25270620 NCBI chr10:13,874,883...13,889,527
Ensembl chr10:13,875,241...13,889,504
JBrowse link
G Hbegf heparin-binding EGF-like growth factor increases expression ISO Heptachlor Epoxide results in increased expression of HBEGF mRNA CTD PMID:25270620 NCBI chr18:28,106,284...28,116,167
Ensembl chr18:28,105,760...28,116,441
JBrowse link
G Hmgcr 3-hydroxy-3-methylglutaryl-CoA reductase increases expression ISO Heptachlor Epoxide results in increased expression of HMGCR mRNA CTD PMID:25270620 NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703
JBrowse link
G Hmgcs2 3-hydroxy-3-methylglutaryl-CoA synthase 2 decreases expression ISO Heptachlor Epoxide results in decreased expression of HMGCS2 mRNA CTD PMID:25270620 NCBI chr 2:185,875,609...185,903,505
Ensembl chr 2:185,875,616...185,902,130
JBrowse link
G Hsd3b3 hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 3 decreases expression ISO Heptachlor Epoxide results in decreased expression of HSD3B3 mRNA CTD PMID:25270620 NCBI chr 2:186,138,044...186,144,024
Ensembl chr 2:186,138,044...186,144,033
JBrowse link
G Hyal1 hyaluronidase 1 decreases expression ISO Heptachlor Epoxide results in decreased expression of HYAL1 mRNA CTD PMID:25270620 NCBI chr 8:108,250,654...108,254,526
Ensembl chr 8:108,250,667...108,260,210
JBrowse link
G Inhbb inhibin subunit beta B increases expression ISO Heptachlor Epoxide results in increased expression of INHBB mRNA CTD PMID:25270620 NCBI chr13:30,530,860...30,536,566
Ensembl chr13:30,530,860...30,537,832
JBrowse link
G Insm1 INSM transcriptional repressor 1 decreases expression ISO Heptachlor Epoxide results in decreased expression of INSM1 mRNA CTD PMID:25270620 NCBI chr 3:133,639,790...133,642,963 JBrowse link
G Itpr3 inositol 1,4,5-trisphosphate receptor, type 3 increases expression ISO Heptachlor Epoxide results in increased expression of ITPR3 mRNA CTD PMID:25270620 NCBI chr20:5,136,968...5,202,339
Ensembl chr20:5,136,441...5,202,337
JBrowse link
G Jmjd6 jumonji domain containing 6, arginine demethylase and lysine hydroxylase increases expression ISO Heptachlor Epoxide results in increased expression of JMJD6 mRNA CTD PMID:25270620 NCBI chr10:102,041,131...102,047,182
Ensembl chr10:102,041,120...102,047,182
JBrowse link
G Klf12 Kruppel-like factor 12 decreases expression ISO Heptachlor Epoxide results in decreased expression of KLF12 mRNA CTD PMID:25270620 NCBI chr15:76,628,778...77,062,000
Ensembl chr15:76,637,654...77,062,056
JBrowse link
G Llgl2 LLGL scribble cell polarity complex component 2 increases expression ISO Heptachlor Epoxide results in increased expression of LLGL2 mRNA CTD PMID:25270620 NCBI chr10:101,050,978...101,086,527
Ensembl chr10:101,051,408...101,086,525
JBrowse link
G Lnx2 ligand of numb-protein X 2 increases expression ISO Heptachlor Epoxide results in increased expression of LNX2 mRNA CTD PMID:25270620 NCBI chr12:8,005,202...8,070,494
Ensembl chr12:8,005,227...8,070,494
JBrowse link
G Lpl lipoprotein lipase decreases expression ISO Heptachlor Epoxide results in decreased expression of LPL mRNA CTD PMID:25270620 NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249
JBrowse link
G Mcam melanoma cell adhesion molecule decreases expression ISO Heptachlor Epoxide results in decreased expression of MCAM mRNA CTD PMID:25270620 NCBI chr 8:44,479,391...44,487,575
Ensembl chr 8:44,479,376...44,487,571
JBrowse link
G Mcl1 MCL1 apoptosis regulator, BCL2 family member increases expression ISO Heptachlor Epoxide results in increased expression of MCL1 mRNA CTD PMID:25270620 NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303
JBrowse link
G Mn1 MN1 proto-oncogene, transcriptional regulator decreases expression ISO Heptachlor Epoxide results in decreased expression of MN1 mRNA CTD PMID:25270620 NCBI chr12:45,184,060...45,220,102
Ensembl chr12:45,183,085...45,221,651
JBrowse link
G Mpeg1 macrophage expressed 1 decreases expression ISO Heptachlor Epoxide results in decreased expression of MPEG1 mRNA CTD PMID:25270620 NCBI chr 1:209,452,176...209,456,692
Ensembl chr 1:209,452,133...209,458,855
JBrowse link
G Msmo1 methylsterol monooxygenase 1 increases expression ISO Heptachlor Epoxide results in increased expression of MSMO1 mRNA CTD PMID:25270620 NCBI chr16:24,980,680...24,997,927
Ensembl chr16:24,980,697...24,998,016
JBrowse link
G Mtarc2 mitochondrial amidoxime reducing component 2 decreases expression ISO Heptachlor Epoxide results in decreased expression of MTARC2 mRNA CTD PMID:25270620 NCBI chr13:96,362,810...96,397,284 JBrowse link
G Mycn MYCN proto-oncogene, bHLH transcription factor decreases expression ISO Heptachlor Epoxide results in decreased expression of MYCN mRNA CTD PMID:25270620 NCBI chr 6:35,717,764...35,723,590
Ensembl chr 6:35,717,764...35,723,590
JBrowse link
G Mylip myosin regulatory light chain interacting protein decreases expression ISO Heptachlor Epoxide results in decreased expression of MYLIP mRNA CTD PMID:25270620 NCBI chr17:19,286,649...19,308,295
Ensembl chr17:19,286,650...19,308,295
JBrowse link
G Myo1f myosin IF increases expression ISO Heptachlor Epoxide results in increased expression of MYO1F mRNA CTD PMID:25270620 NCBI chr 7:14,363,340...14,413,911
Ensembl chr 7:14,363,350...14,413,911
JBrowse link
G Ndrg1 N-myc downstream regulated 1 increases expression ISO Heptachlor Epoxide results in increased expression of NDRG1 mRNA CTD PMID:25270620 NCBI chr 7:98,684,487...98,725,869
Ensembl chr 7:98,684,487...98,725,880
JBrowse link
G Nefl neurofilament light chain decreases expression ISO Heptachlor Epoxide results in decreased expression of NEFL mRNA CTD PMID:25270620 NCBI chr15:42,301,920...42,305,793
Ensembl chr15:42,301,916...42,305,793
JBrowse link
G Nnt nicotinamide nucleotide transhydrogenase decreases expression ISO Heptachlor Epoxide results in decreased expression of NNT mRNA CTD PMID:25270620 NCBI chr 2:51,411,413...51,505,125
Ensembl chr 2:51,411,413...51,504,823
JBrowse link
G Nphs1 NPHS1 adhesion molecule, nephrin increases expression ISO Heptachlor Epoxide results in increased expression of NPHS1 mRNA CTD PMID:25270620 NCBI chr 1:85,720,812...85,749,079
Ensembl chr 1:85,720,812...85,749,078
JBrowse link
G Nr1i2 nuclear receptor subfamily 1, group I, member 2 multiple interactions ISO Heptachlor Epoxide binds to and results in increased activity of NR1I2 protein CTD PMID:21115097 NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
JBrowse link
G Nr1i3 nuclear receptor subfamily 1, group I, member 3 increases activity ISO Heptachlor Epoxide results in increased activity of NR1I3 protein CTD PMID:28927721 NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906
JBrowse link
G Orc2 origin recognition complex, subunit 2 decreases expression ISO Heptachlor Epoxide results in decreased expression of ORC2 mRNA CTD PMID:25270620 NCBI chr 9:60,001,631...60,038,301
Ensembl chr 9:60,001,910...60,038,195
JBrowse link
G Peg3 paternally expressed 3 decreases expression ISO Heptachlor Epoxide results in decreased expression of PEG3 mRNA CTD PMID:25270620 NCBI chr 1:67,097,874...67,124,692
Ensembl chr 1:67,097,904...67,124,671
JBrowse link
G Pfkfb1 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 1 decreases expression ISO Heptachlor Epoxide results in decreased expression of PFKFB1 mRNA CTD PMID:25270620 NCBI chr  X:19,508,522...19,562,165
Ensembl chr  X:19,508,546...19,562,182
JBrowse link
G Pgr progesterone receptor multiple interactions
increases expression
ISO ICI 164384 inhibits the reaction [Heptachlor Epoxide results in increased expression of PGR mRNA] CTD PMID:16242299 NCBI chr 8:6,073,216...6,131,552
Ensembl chr 8:6,072,673...6,131,344
JBrowse link
G Phlda3 pleckstrin homology-like domain, family A, member 3 decreases expression ISO Heptachlor Epoxide results in decreased expression of PHLDA3 mRNA CTD PMID:25270620 NCBI chr13:47,193,250...47,196,335
Ensembl chr13:47,193,086...47,196,335
JBrowse link
G Pla2g12a phospholipase A2, group XIIA increases expression ISO Heptachlor Epoxide results in increased expression of PLA2G12A mRNA CTD PMID:25270620 NCBI chr 2:218,436,450...218,452,760
Ensembl chr 2:218,436,513...218,452,740
JBrowse link
G Plcg1 phospholipase C, gamma 1 increases expression ISO Heptachlor Epoxide results in increased expression of PLCG1 protein CTD PMID:11246134 NCBI chr 3:149,385,587...149,416,330
Ensembl chr 3:149,385,587...149,416,330
JBrowse link
G Plekha5 pleckstrin homology domain containing A5 increases expression ISO Heptachlor Epoxide results in increased expression of PLEKHA5 mRNA CTD PMID:25270620 NCBI chr 4:173,333,891...173,503,546
Ensembl chr 4:173,334,055...173,503,546
JBrowse link
G Porcn porcupine O-acyltransferase increases expression ISO Heptachlor Epoxide results in increased expression of PORCN mRNA CTD PMID:25270620 NCBI chr  X:14,285,864...14,298,481
Ensembl chr  X:14,285,871...14,298,481
JBrowse link
G Prkce protein kinase C, epsilon increases expression
decreases expression
ISO Heptachlor Epoxide results in increased expression of PRKCE protein alternative form
Heptachlor Epoxide results in decreased expression of PRKCE protein alternative form
CTD PMID:11170310 PMID:11246134 NCBI chr 6:7,965,048...8,451,966
Ensembl chr 6:7,965,048...8,451,719
JBrowse link
G Psmg3 proteasome assembly chaperone 3 decreases expression ISO Heptachlor Epoxide results in decreased expression of PSMG3 mRNA CTD PMID:25270620 NCBI chr12:14,809,234...14,812,347
Ensembl chr12:14,809,450...14,812,342
JBrowse link
G Ptcd1 pentatricopeptide repeat domain 1 decreases expression ISO Heptachlor Epoxide results in decreased expression of PTCD1 mRNA CTD PMID:25270620 NCBI chr12:9,445,656...9,463,508
Ensembl chr12:9,445,714...9,463,508
JBrowse link
G Ptges prostaglandin E synthase increases expression ISO Heptachlor Epoxide results in increased expression of PTGES mRNA CTD PMID:25270620 NCBI chr 3:14,177,892...14,189,236 JBrowse link
G Rdh11 retinol dehydrogenase 11 increases expression ISO Heptachlor Epoxide results in increased expression of RDH11 mRNA CTD PMID:25270620 NCBI chr 6:97,979,377...97,995,252
Ensembl chr 6:97,979,378...97,995,252
JBrowse link
G Rnf145 ring finger protein 145 decreases expression ISO Heptachlor Epoxide results in decreased expression of RNF145 mRNA CTD PMID:25270620 NCBI chr10:29,011,548...29,050,785
Ensembl chr10:29,011,548...29,050,781
JBrowse link
G Scd stearoyl-CoA desaturase decreases expression ISO Heptachlor Epoxide results in decreased expression of SCD1 mRNA CTD PMID:25270620 NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562
JBrowse link
G Scd2 stearoyl-Coenzyme A desaturase 2 decreases expression ISO Heptachlor Epoxide results in decreased expression of SCD2 mRNA CTD PMID:25270620 NCBI chr 1:243,169,171...243,182,231
Ensembl chr 1:243,169,236...243,182,232
JBrowse link
G Sdc2 syndecan 2 decreases expression ISO Heptachlor Epoxide results in decreased expression of SDC2 mRNA CTD PMID:25270620 NCBI chr 7:64,127,185...64,239,885
Ensembl chr 7:64,127,110...64,241,081
JBrowse link
G Slc16a2 solute carrier family 16 member 2 decreases expression ISO Heptachlor Epoxide results in decreased expression of SLC16A2 mRNA CTD PMID:25270620 NCBI chr  X:68,725,365...68,848,572
Ensembl chr  X:68,723,261...68,848,771
JBrowse link
G Slc18a2 solute carrier family 18 member A2 multiple interactions ISO Heptachlor Epoxide inhibits the reaction [SLC18A2 protein results in increased uptake of Dopamine] CTD PMID:10499361 NCBI chr 1:258,413,748...258,449,143
Ensembl chr 1:258,413,959...258,448,325
JBrowse link
G Slc25a51 solute carrier family 25, member 51 increases expression ISO Heptachlor Epoxide results in increased expression of SLC25A51 mRNA CTD PMID:25270620
G Slc3a2 solute carrier family 3 member 2 increases expression ISO Heptachlor Epoxide results in increased expression of SLC3A2 mRNA CTD PMID:25270620 NCBI chr 1:205,604,468...205,618,931
Ensembl chr 1:205,604,468...205,618,931
JBrowse link
G Sntb2 syntrophin, beta 2 increases expression ISO Heptachlor Epoxide results in increased expression of SNTB2 mRNA CTD PMID:25270620 NCBI chr19:34,831,657...34,922,325
Ensembl chr19:34,831,584...34,914,113
JBrowse link
G Sqor sulfide quinone oxidoreductase decreases expression ISO Heptachlor Epoxide results in decreased expression of SQOR mRNA CTD PMID:25270620 NCBI chr 3:109,841,225...109,886,724
Ensembl chr 3:109,841,250...109,960,778
JBrowse link
G Srsf2 serine and arginine rich splicing factor 2 decreases expression ISO Heptachlor Epoxide results in decreased expression of SRSF2 mRNA CTD PMID:25270620 NCBI chr10:102,052,158...102,055,365
Ensembl chr10:102,052,314...102,055,338
JBrowse link
G Srsf9 serine and arginine rich splicing factor 9 decreases expression ISO Heptachlor Epoxide results in decreased expression of SRSF9 mRNA CTD PMID:25270620 NCBI chr12:41,278,225...41,284,502
Ensembl chr12:41,275,687...41,284,499
JBrowse link
G Steap1 STEAP family member 1 increases expression ISO Heptachlor Epoxide results in increased expression of STEAP1 mRNA CTD PMID:25270620 NCBI chr 4:28,276,972...28,287,484
Ensembl chr 4:28,276,909...28,287,479
JBrowse link
G Steap2 STEAP2 metalloreductase increases expression ISO Heptachlor Epoxide results in increased expression of STEAP2 mRNA CTD PMID:25270620 NCBI chr 4:28,347,769...28,368,177
Ensembl chr 4:28,348,362...28,375,791
JBrowse link
G Stra8 stimulated by retinoic acid 8 increases expression ISO Heptachlor Epoxide results in increased expression of STRA8 mRNA CTD PMID:25270620 NCBI chr 4:63,601,443...63,624,777
Ensembl chr 4:63,601,604...63,624,771
JBrowse link
G Tamalin trafficking regulator and scaffold protein tamalin increases expression ISO Heptachlor Epoxide results in increased expression of TAMALIN mRNA CTD PMID:25270620 NCBI chr 7:132,338,900...132,359,519
Ensembl chr 7:132,338,900...132,346,666
JBrowse link
G Tceal8 transcription elongation factor A like 8 decreases expression ISO Heptachlor Epoxide results in decreased expression of TCEAL8 mRNA CTD PMID:25270620 NCBI chr  X:99,171,307...99,173,377
Ensembl chr  X:99,171,177...99,173,710
JBrowse link
G Tdo2 tryptophan 2,3-dioxygenase decreases expression ISO Heptachlor Epoxide results in decreased expression of TDO2 mRNA CTD PMID:25270620 NCBI chr 2:167,269,581...167,287,511
Ensembl chr 2:167,269,579...167,287,511
JBrowse link
G Tefm transcription elongation factor, mitochondrial increases expression ISO Heptachlor Epoxide results in increased expression of TEFM mRNA CTD PMID:25270620 NCBI chr10:65,119,657...65,124,233
Ensembl chr10:65,119,659...65,124,486
JBrowse link
G Tff1 trefoil factor 1 increases expression
multiple interactions
ISO Heptachlor Epoxide results in increased expression of TFF1 mRNA
ICI 164384 inhibits the reaction [Heptachlor Epoxide results in increased expression of TFF1 mRNA]
CTD PMID:16242299 NCBI chr20:9,235,736...9,239,597
Ensembl chr20:9,235,736...9,239,597
JBrowse link
G Tmem254 transmembrane protein 254 decreases expression ISO Heptachlor Epoxide results in decreased expression of TMEM254 mRNA CTD PMID:25270620 NCBI chr16:1,503,931...1,507,819
Ensembl chr16:1,503,933...1,507,895
JBrowse link
G Tnfaip3 TNF alpha induced protein 3 decreases expression ISO Heptachlor Epoxide results in decreased expression of TNFAIP3 mRNA CTD PMID:25270620 NCBI chr 1:13,709,211...13,724,291
Ensembl chr 1:13,709,206...13,725,282
JBrowse link
G Tns1 tensin 1 decreases expression ISO Heptachlor Epoxide results in decreased expression of TNS1 mRNA CTD PMID:25270620 NCBI chr 9:75,491,886...75,702,853
Ensembl chr 9:75,495,814...75,703,225
JBrowse link
G Tspo translocator protein increases expression EXP Heptachlor Epoxide results in increased expression of TSPO CTD PMID:14699885 NCBI chr 7:114,720,188...114,730,450
Ensembl chr 7:114,720,188...114,730,450
JBrowse link
G Ttc39b tetratricopeptide repeat domain 39B increases expression ISO Heptachlor Epoxide results in increased expression of TTC39B mRNA CTD PMID:25270620 NCBI chr 5:97,603,329...97,708,103
Ensembl chr 5:97,609,392...97,736,270
JBrowse link
G Usp14 ubiquitin specific peptidase 14 increases expression ISO Heptachlor Epoxide results in increased expression of USP14 mRNA CTD PMID:25270620 NCBI chr18:1,018,111...1,057,727
Ensembl chr18:1,019,400...1,057,519
JBrowse link
G Zmym3 zinc finger MYM-type containing 3 increases expression ISO Heptachlor Epoxide results in increased expression of ZMYM3 mRNA CTD PMID:25270620 NCBI chr  X:66,528,585...66,544,234
Ensembl chr  X:66,528,585...66,544,782
JBrowse link
lasalocid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Mapt microtubule-associated protein tau decreases expression ISO Lasalocid results in decreased expression of MAPT protein CTD PMID:16930453 NCBI chr10:89,138,644...89,236,137
Ensembl chr10:89,138,627...89,236,129
JBrowse link
saracatinib term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Cav1 caveolin 1 multiple interactions EXP saracatinib inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of CAV1 protein] CTD PMID:26357463 NCBI chr 4:45,640,624...45,673,708
Ensembl chr 4:45,634,918...45,673,705
JBrowse link
G Csk C-terminal Src kinase decreases activity
multiple interactions
ISO saracatinib results in decreased activity of CSK protein
saracatinib inhibits the reaction [CSK protein results in decreased expression of CYP7A1 mRNA]
CTD PMID:20371703 NCBI chr 8:58,029,748...58,048,742
Ensembl chr 8:58,029,749...58,048,292
JBrowse link
G Cyp1a2 cytochrome P450, family 1, subfamily a, polypeptide 2 increases oxidation ISO CYP1A2 protein results in increased oxidation of saracatinib CTD PMID:27769111 NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
JBrowse link
G Cyp24a1 cytochrome P450, family 24, subfamily a, polypeptide 1 multiple interactions ISO saracatinib inhibits the reaction [Calcitriol results in increased expression of CYP24A1 mRNA]; saracatinib inhibits the reaction [lithocholic acid acetate results in increased expression of CYP24A1 mRNA] CTD PMID:20371703 NCBI chr 3:159,275,947...159,290,383
Ensembl chr 3:159,275,947...159,290,383
JBrowse link
G Cyp2d4 cytochrome P450, family 2, subfamily d, polypeptide 4 increases oxidation ISO CYP2D6 protein results in increased oxidation of saracatinib CTD PMID:27769111 NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759
JBrowse link
G Cyp3a2 cytochrome P450, family 3, subfamily a, polypeptide 2 increases oxidation ISO CYP3A4 protein results in increased oxidation of saracatinib CTD PMID:27769111 NCBI chr12:9,207,986...9,230,038
Ensembl chr12:9,015,383...9,285,008
JBrowse link
G Cyp7a1 cytochrome P450 family 7 subfamily A member 1 increases expression
multiple interactions
ISO saracatinib results in increased expression of CYP7A1 mRNA
saracatinib inhibits the reaction [Calcitriol results in decreased expression of CYP7A1 mRNA]; saracatinib inhibits the reaction [CSK protein results in decreased expression of CYP7A1 mRNA]; saracatinib inhibits the reaction [lithocholic acid acetate results in decreased expression of CYP7A1 mRNA]
CTD PMID:20371703 NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688
JBrowse link
G L1cam L1 cell adhesion molecule decreases phosphorylation ISO saracatinib results in decreased phosphorylation of L1CAM protein CTD PMID:29109170 NCBI chr  X:151,597,270...151,623,776
Ensembl chr  X:151,597,277...151,623,857
JBrowse link
G Pkmyt1 protein kinase, membrane associated tyrosine/threonine 1 decreases activity ISO saracatinib results in decreased activity of PKMYT1 protein CTD PMID:29941193 NCBI chr10:12,748,221...12,758,995
Ensembl chr10:12,748,237...12,758,995
JBrowse link
G Src SRC proto-oncogene, non-receptor tyrosine kinase multiple interactions ISO saracatinib binds to and affects the activity of SRC protein CTD PMID:22470466 NCBI chr 3:146,091,969...146,139,492
Ensembl chr 3:146,091,841...146,139,476
JBrowse link
G Vdr vitamin D receptor multiple interactions ISO saracatinib inhibits the reaction [Calcitriol results in increased phosphorylation of VDR protein]; saracatinib inhibits the reaction [lithocholic acid acetate results in increased phosphorylation of VDR protein] CTD PMID:20371703 NCBI chr 7:128,987,981...129,037,677
Ensembl chr 7:128,987,981...129,037,677
JBrowse link
venetoclax term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcg2 ATP binding cassette subfamily G member 2 affects binding ISO venetoclax binds to ABCG2 protein CTD PMID:33954893 NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
JBrowse link
G Bcl2 BCL2, apoptosis regulator decreases activity ISO venetoclax results in decreased activity of BCL2 protein CTD PMID:26214592 NCBI chr13:22,689,783...22,853,920 JBrowse link
G Birc5 baculoviral IAP repeat-containing 5 multiple interactions ISO [YM 155 co-treated with venetoclax] results in decreased expression of BIRC5 protein CTD PMID:31837377 NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
JBrowse link
G Casp3 caspase 3 multiple interactions ISO [venetoclax co-treated with YM 155] results in increased cleavage of CASP3 protein CTD PMID:31837377 NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
JBrowse link
G Casp9 caspase 9 multiple interactions ISO [venetoclax co-treated with YM 155] results in increased cleavage of CASP9 protein CTD PMID:31837377 NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
JBrowse link
G Mcl1 MCL1 apoptosis regulator, BCL2 family member increases expression
multiple interactions
ISO venetoclax results in increased expression of MCL1 protein
[YM 155 co-treated with venetoclax] results in decreased expression of MCL1 protein
CTD PMID:31837377 NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303
JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions ISO [venetoclax co-treated with YM 155] results in increased cleavage of PARP1 protein CTD PMID:31837377 NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
JBrowse link

Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 19823
    chemical entity 19823
      atom 19821
        nonmetal atom 19709
          oxygen atom 19447
            oxygen molecular entity 19447
              organooxygen compound 19024
                oxacycle 17622
                  oxanes 212
                    (+)-cis-Linalool 3,7-oxide 0
                    (1S,2S,4S,5R)-1,8-Epoxy-p-menthane-2,5-diol 0
                    (2-formyloxan-3-yl) acetate 0
                    (3R,6aR,8R,10aR)-8-[2-(cyclopropylmethylamino)-2-oxoethyl]-N-(3,5-dimethyl-4-isoxazolyl)-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocine-1-carboxamide 0
                    (3R,6aR,8S,10aR)-8-[2-(cyclopropylmethylamino)-2-oxoethyl]-N-(3,5-dimethyl-4-isoxazolyl)-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocine-1-carboxamide 0
                    (3R,6aS,8R,10aS)-8-[2-(cyclopropylmethylamino)-2-oxoethyl]-N-(3,5-dimethyl-1,2-oxazol-4-yl)-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocine-1-carboxamide 0
                    (3R,6aS,8S,10aS)-8-[2-(cyclopropylmethylamino)-2-oxoethyl]-N-(3,5-dimethyl-4-isoxazolyl)-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocine-1-carboxamide 0
                    (3S,6aR,8R,10aR)-8-[2-(cyclopropylmethylamino)-2-oxoethyl]-N-(3,5-dimethyl-4-isoxazolyl)-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocine-1-carboxamide 0
                    (3S,6aR,8S,10aR)-8-[2-(cyclopropylmethylamino)-2-oxoethyl]-N-(3,5-dimethyl-4-isoxazolyl)-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocine-1-carboxamide 0
                    (3S,6aS,8R,10aS)-8-[2-(cyclopropylmethylamino)-2-oxoethyl]-N-(3,5-dimethyl-4-isoxazolyl)-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocine-1-carboxamide 0
                    (3S,6aS,8S,10aS)-8-[2-(cyclopropylmethylamino)-2-oxoethyl]-N-(3,5-dimethyl-4-isoxazolyl)-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocine-1-carboxamide 0
                    2-Hydroxycineol 0
                    2-[(3R,6aR,8R,10aR)-1-(cyclopentylmethyl)-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[3-(dimethylamino)propyl]acetamide 0
                    2-[(3R,6aR,8R,10aR)-1-[cyclopentyl(oxo)methyl]-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N,N-dimethylacetamide 0
                    2-[(3R,6aR,8R,10aR)-3-hydroxy-1,2,3,4,6,6a,8,9,10,10a-decahydropyrano[2,3-c][1,5]oxazocin-8-yl]acetic acid methyl ester 0
                    2-[(3R,6aR,8R,10aR)-3-hydroxy-1-(3,3,3-trifluoropropyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(cyclohexylmethyl)acetamide 0
                    2-[(3R,6aR,8R,10aR)-3-hydroxy-1-(3,3,3-trifluoropropyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]acetic acid methyl ester 0
                    2-[(3R,6aR,8R,10aR)-3-hydroxy-1-(4-oxanylmethyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(cyclopropylmethyl)acetamide 0
                    2-[(3R,6aR,8R,10aR)-3-hydroxy-1-[4-oxanyl(oxo)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-ethylacetamide 0
                    2-[(3R,6aR,8R,10aR)-3-hydroxy-1-[oxo(propylamino)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]acetic acid 0
                    2-[(3R,6aR,8R,10aR)-3-hydroxy-1-methyl-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-cyclobutylacetamide 0
                    2-[(3R,6aR,8S,10aR)-1-[cyclopentyl(oxo)methyl]-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N,N-dimethylacetamide 0
                    2-[(3R,6aR,8S,10aR)-3-hydroxy-1,2,3,4,6,6a,8,9,10,10a-decahydropyrano[2,3-c][1,5]oxazocin-8-yl]acetic acid methyl ester 0
                    2-[(3R,6aR,8S,10aR)-3-hydroxy-1-(3,3,3-trifluoropropyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(cyclohexylmethyl)acetamide 0
                    2-[(3R,6aR,8S,10aR)-3-hydroxy-1-[4-oxanyl(oxo)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-ethylacetamide 0
                    2-[(3R,6aR,8S,10aR)-3-hydroxy-1-[oxo(propylamino)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]acetic acid 0
                    2-[(3R,6aR,8S,10aR)-3-hydroxy-1-methyl-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-cyclobutylacetamide 0
                    2-[(3R,6aR,8S,10aR)-3-hydroxy-1-methylsulfonyl-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(phenylmethyl)acetamide 0
                    2-[(3R,6aS,8R,10aS)-1-(cyclopentanecarbonyl)-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N,N-dimethylacetamide 0
                    2-[(3R,6aS,8R,10aS)-1-(cyclopentylmethyl)-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[3-(dimethylamino)propyl]acetamide 0
                    2-[(3R,6aS,8R,10aS)-3-hydroxy-1,2,3,4,6,6a,8,9,10,10a-decahydropyrano[2,3-c][1,5]oxazocin-8-yl]acetic acid methyl ester 0
                    2-[(3R,6aS,8R,10aS)-3-hydroxy-1-(3,3,3-trifluoropropyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]acetic acid methyl ester 0
                    2-[(3R,6aS,8R,10aS)-3-hydroxy-1-(4-oxanylmethyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(cyclopropylmethyl)acetamide 0
                    2-[(3R,6aS,8R,10aS)-3-hydroxy-1-(oxane-4-carbonyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-ethylacetamide 0
                    2-[(3R,6aS,8R,10aS)-3-hydroxy-1-methyl-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-cyclobutylacetamide 0
                    2-[(3R,6aS,8R,10aS)-3-hydroxy-1-methylsulfonyl-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-benzylacetamide 0
                    2-[(3R,6aS,8S,10aS)-1-(cyclopentylmethyl)-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[3-(dimethylamino)propyl]acetamide 0
                    2-[(3R,6aS,8S,10aS)-1-[cyclopentyl(oxo)methyl]-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N,N-dimethylacetamide 0
                    2-[(3R,6aS,8S,10aS)-3-hydroxy-1,2,3,4,6,6a,8,9,10,10a-decahydropyrano[2,3-c][1,5]oxazocin-8-yl]acetic acid methyl ester 0
                    2-[(3R,6aS,8S,10aS)-3-hydroxy-1-(3,3,3-trifluoropropyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(cyclohexylmethyl)acetamide 0
                    2-[(3R,6aS,8S,10aS)-3-hydroxy-1-(4-oxanylmethyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(cyclopropylmethyl)acetamide 0
                    2-[(3R,6aS,8S,10aS)-3-hydroxy-1-[4-oxanyl(oxo)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-ethylacetamide 0
                    2-[(3R,6aS,8S,10aS)-3-hydroxy-1-methyl-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(1S)-1-phenylethyl]acetamide 0
                    2-[(3R,6aS,8S,10aS)-3-hydroxy-1-methyl-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-cyclobutylacetamide 0
                    2-[(3R,6aS,8S,10aS)-3-hydroxy-1-methyl-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-cyclopentylacetamide 0
                    2-[(3R,6aS,8S,10aS)-3-hydroxy-1-methylsulfonyl-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(phenylmethyl)acetamide 0
                    2-[(3S,6aR,8R,10aR)-1-(cyclopentylmethyl)-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[3-(dimethylamino)propyl]acetamide 0
                    2-[(3S,6aR,8R,10aR)-3-hydroxy-1,2,3,4,6,6a,8,9,10,10a-decahydropyrano[2,3-c][1,5]oxazocin-8-yl]acetic acid methyl ester 0
                    2-[(3S,6aR,8R,10aR)-3-hydroxy-1-(1-oxopropyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-methylacetamide 0
                    2-[(3S,6aR,8R,10aR)-3-hydroxy-1-(3,3,3-trifluoropropyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(cyclohexylmethyl)acetamide 0
                    2-[(3S,6aR,8R,10aR)-3-hydroxy-1-(3,3,3-trifluoropropyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]acetic acid methyl ester 0
                    2-[(3S,6aR,8R,10aR)-3-hydroxy-1-(4-oxanylmethyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(cyclopropylmethyl)acetamide 0
                    2-[(3S,6aR,8R,10aR)-3-hydroxy-1-[4-oxanyl(oxo)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-ethylacetamide 0
                    2-[(3S,6aR,8R,10aR)-3-hydroxy-1-methyl-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-cyclobutylacetamide 0
                    2-[(3S,6aR,8S,10aR)-1-(cyclopentylmethyl)-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[3-(dimethylamino)propyl]acetamide 0
                    2-[(3S,6aR,8S,10aR)-1-[cyclopentyl(oxo)methyl]-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N,N-dimethylacetamide 0
                    2-[(3S,6aR,8S,10aR)-3-hydroxy-1,2,3,4,6,6a,8,9,10,10a-decahydropyrano[2,3-c][1,5]oxazocin-8-yl]acetic acid methyl ester 0
                    2-[(3S,6aR,8S,10aR)-3-hydroxy-1-(3,3,3-trifluoropropyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(cyclohexylmethyl)acetamide 0
                    2-[(3S,6aR,8S,10aR)-3-hydroxy-1-(3,3,3-trifluoropropyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]acetic acid methyl ester 0
                    2-[(3S,6aR,8S,10aR)-3-hydroxy-1-(4-oxanylmethyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(cyclopropylmethyl)acetamide 0
                    2-[(3S,6aR,8S,10aR)-3-hydroxy-1-(oxane-4-carbonyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-ethylacetamide 0
                    2-[(3S,6aR,8S,10aR)-3-hydroxy-1-methyl-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-cyclobutylacetamide 0
                    2-[(3S,6aS,8R,10aS)-1-(cyclopentylmethyl)-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[3-(dimethylamino)propyl]acetamide 0
                    2-[(3S,6aS,8R,10aS)-1-[cyclopentyl(oxo)methyl]-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N,N-dimethylacetamide 0
                    2-[(3S,6aS,8R,10aS)-3-hydroxy-1,2,3,4,6,6a,8,9,10,10a-decahydropyrano[2,3-c][1,5]oxazocin-8-yl]acetic acid methyl ester 0
                    2-[(3S,6aS,8R,10aS)-3-hydroxy-1-(3,3,3-trifluoropropyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(cyclohexylmethyl)acetamide 0
                    2-[(3S,6aS,8R,10aS)-3-hydroxy-1-(4-oxanylmethyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(cyclopropylmethyl)acetamide 0
                    2-[(3S,6aS,8R,10aS)-3-hydroxy-1-(propylcarbamoyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]acetic acid 0
                    2-[(3S,6aS,8R,10aS)-3-hydroxy-1-[4-oxanyl(oxo)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-ethylacetamide 0
                    2-[(3S,6aS,8R,10aS)-3-hydroxy-1-methyl-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-cyclobutylacetamide 0
                    2-[(3S,6aS,8R,10aS)-3-hydroxy-1-methylsulfonyl-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(phenylmethyl)acetamide 0
                    2-[(3S,6aS,8S,10aS)-1-(cyclopentylmethyl)-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[3-(dimethylamino)propyl]acetamide 0
                    2-[(3S,6aS,8S,10aS)-1-[cyclopentyl(oxo)methyl]-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N,N-dimethylacetamide 0
                    2-[(3S,6aS,8S,10aS)-3-hydroxy-1,2,3,4,6,6a,8,9,10,10a-decahydropyrano[2,3-c][1,5]oxazocin-8-yl]acetic acid methyl ester 0
                    2-[(3S,6aS,8S,10aS)-3-hydroxy-1-(3,3,3-trifluoropropyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(cyclohexylmethyl)acetamide 0
                    2-[(3S,6aS,8S,10aS)-3-hydroxy-1-(3,3,3-trifluoropropyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]acetic acid methyl ester 0
                    2-[(3S,6aS,8S,10aS)-3-hydroxy-1-(4-oxanylmethyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(cyclopropylmethyl)acetamide 0
                    2-[(3S,6aS,8S,10aS)-3-hydroxy-1-[4-oxanyl(oxo)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-ethylacetamide 0
                    2-[(3S,6aS,8S,10aS)-3-hydroxy-1-[oxo(propylamino)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]acetic acid 0
                    2-[(3S,6aS,8S,10aS)-3-hydroxy-1-methyl-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-cyclobutylacetamide 0
                    2-chloro-N-[2-(2,2-dimethyl-4-phenyl-4-oxanyl)ethyl]acetamide 0
                    3-imino-1,5,5-trimethyl-2-oxabicyclo[2.2.1]heptane-4,7,7-tricarbonitrile 0
                    Abyssomicin I 0
                    Aurothioglucose 17
                    Avermectin A2a aglycone 0
                    Avermectin A2b aglycone 0
                    Avermectin B2b aglycone 0
                    Bis(2,3-epoxycyclopentyl)ether 0
                    Bisabolol oxide A 0
                    Caespitol 0
                    Chlorochrymorin 0
                    Chrycorin 0
                    Clarycet 0
                    Cochlioquinone A 0
                    Coronarian 0
                    Cunaniol 0
                    Cytosporin D 0
                    D-1,5-Anhydrofructose 0
                    Daucol 0
                    Epomediol 4
                    Epoxyeremopetasinorol 0
                    Heptachlor epoxide 112
                    Hymenoxon 0
                    Ichthyotherol 0
                    Isocaespitol 0
                    Linalool oxide (trans-pyranoid) 0
                    Linalool oxide III 0
                    Linalool oxide pyranoside 0
                    Microhelenin A 0
                    N-(4-\{4-amino-1-[1-(tetrahydro-2H-pyran-4-yl)piperidin-4-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl\}-2-methoxyphenyl)-1-methyl-1H-indole-2-carboxamide 0
                    N-(5-\{[(5-tert-butyl-1,3-oxazol-2-yl)methyl]sulfanyl\}-1,3-thiazol-2-yl)tetrahydro-2H-pyran-4-carboxamide 0
                    N-[2-morpholin-4-yl-1-(morpholin-4-ylmethyl)ethyl]-3-nitro-5-(3,4,5-trihydroxy-6-hydroxymethyltetrahydropyran-2-yloxy)benzamide 0
                    N-\{3-[4-(3-aminopropyl)piperazin-1-yl]propyl\}-3-(2-thiophen-2-ylacetylamino)-5-(3,4,5-trihydroxy-6-hydroxymethyltetrahydropyran-2-yloxy)benzamide 0
                    N-tert-butyl-7,7-dimethyl-2-oxo-1,8-dioxaspiro[4.5]decane-4-carboxamide 0
                    Oryzalic acid A 0
                    Oxychlordane 0
                    PF-4800567 0
                    Plaunol D 0
                    Smardaesidin C, (rel)- 0
                    Tepraloxydim 0
                    Tetrahydro-2,5-dimethyl-2H-pyranmethanol 0
                    Tritoniopsin A, rel- 0
                    Tritoniopsin B, rel- 0
                    Tritoniopsin C, rel- 0
                    Tritoniopsin D 0
                    Vulgarolide 0
                    \{(2R,3S,4S,5S)-3,4-dihydroxy-5-(hydroxymethyl)-5-[(2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-methoxytetrahydro-2H-pyran-2-yloxy]tetrahydrofuran-2-yl\}methyl nonanoate 0
                    alpha-Bisabolol oxide C 0
                    auricin 0
                    bafilomycin A1 70
                    daibuoxide 0
                    gilteritinib 0
                    glutaric anhydride 0
                    hygrolidin 0
                    indanomycin 0
                    lasalocid 1
                    linaloyl oxide 0
                    marinolic acid C 0
                    methyl 2-[(3R,6aR,8S,10aR)-3-hydroxy-1-(3,3,3-trifluoropropyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]acetate 0
                    methyl 2-[(3R,6aS,8S,10aS)-3-hydroxy-1-(3,3,3-trifluoropropyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]acetate 0
                    methyl 2-[(3S,6aS,8R,10aS)-3-hydroxy-1-(3,3,3-trifluoropropyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]acetate 0
                    mupirocin 0
                    myriaporone 3 0
                    oxane + 0
                    pederin 0
                    rose oxide + 0
                    saracatinib 11
                    venetoclax 7
Path 2
Term Annotations click to browse term
  CHEBI ontology 19823
    subatomic particle 19821
      composite particle 19821
        hadron 19821
          baryon 19821
            nucleon 19821
              atomic nucleus 19821
                atom 19821
                  main group element atom 19720
                    p-block element atom 19720
                      carbon group element atom 19643
                        carbon atom 19633
                          organic molecular entity 19633
                            organic molecule 19572
                              organic cyclic compound 19366
                                organic heterocyclic compound 18604
                                  organic heteromonocyclic compound 17116
                                    oxanes 212
                                      (+)-cis-Linalool 3,7-oxide 0
                                      (1S,2S,4S,5R)-1,8-Epoxy-p-menthane-2,5-diol 0
                                      (2-formyloxan-3-yl) acetate 0
                                      (3R,6aR,8R,10aR)-8-[2-(cyclopropylmethylamino)-2-oxoethyl]-N-(3,5-dimethyl-4-isoxazolyl)-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocine-1-carboxamide 0
                                      (3R,6aR,8S,10aR)-8-[2-(cyclopropylmethylamino)-2-oxoethyl]-N-(3,5-dimethyl-4-isoxazolyl)-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocine-1-carboxamide 0
                                      (3R,6aS,8R,10aS)-8-[2-(cyclopropylmethylamino)-2-oxoethyl]-N-(3,5-dimethyl-1,2-oxazol-4-yl)-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocine-1-carboxamide 0
                                      (3R,6aS,8S,10aS)-8-[2-(cyclopropylmethylamino)-2-oxoethyl]-N-(3,5-dimethyl-4-isoxazolyl)-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocine-1-carboxamide 0
                                      (3S,6aR,8R,10aR)-8-[2-(cyclopropylmethylamino)-2-oxoethyl]-N-(3,5-dimethyl-4-isoxazolyl)-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocine-1-carboxamide 0
                                      (3S,6aR,8S,10aR)-8-[2-(cyclopropylmethylamino)-2-oxoethyl]-N-(3,5-dimethyl-4-isoxazolyl)-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocine-1-carboxamide 0
                                      (3S,6aS,8R,10aS)-8-[2-(cyclopropylmethylamino)-2-oxoethyl]-N-(3,5-dimethyl-4-isoxazolyl)-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocine-1-carboxamide 0
                                      (3S,6aS,8S,10aS)-8-[2-(cyclopropylmethylamino)-2-oxoethyl]-N-(3,5-dimethyl-4-isoxazolyl)-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocine-1-carboxamide 0
                                      2-Hydroxycineol 0
                                      2-[(3R,6aR,8R,10aR)-1-(cyclopentylmethyl)-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[3-(dimethylamino)propyl]acetamide 0
                                      2-[(3R,6aR,8R,10aR)-1-[cyclopentyl(oxo)methyl]-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N,N-dimethylacetamide 0
                                      2-[(3R,6aR,8R,10aR)-3-hydroxy-1,2,3,4,6,6a,8,9,10,10a-decahydropyrano[2,3-c][1,5]oxazocin-8-yl]acetic acid methyl ester 0
                                      2-[(3R,6aR,8R,10aR)-3-hydroxy-1-(3,3,3-trifluoropropyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(cyclohexylmethyl)acetamide 0
                                      2-[(3R,6aR,8R,10aR)-3-hydroxy-1-(3,3,3-trifluoropropyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]acetic acid methyl ester 0
                                      2-[(3R,6aR,8R,10aR)-3-hydroxy-1-(4-oxanylmethyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(cyclopropylmethyl)acetamide 0
                                      2-[(3R,6aR,8R,10aR)-3-hydroxy-1-[4-oxanyl(oxo)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-ethylacetamide 0
                                      2-[(3R,6aR,8R,10aR)-3-hydroxy-1-[oxo(propylamino)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]acetic acid 0
                                      2-[(3R,6aR,8R,10aR)-3-hydroxy-1-methyl-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-cyclobutylacetamide 0
                                      2-[(3R,6aR,8S,10aR)-1-[cyclopentyl(oxo)methyl]-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N,N-dimethylacetamide 0
                                      2-[(3R,6aR,8S,10aR)-3-hydroxy-1,2,3,4,6,6a,8,9,10,10a-decahydropyrano[2,3-c][1,5]oxazocin-8-yl]acetic acid methyl ester 0
                                      2-[(3R,6aR,8S,10aR)-3-hydroxy-1-(3,3,3-trifluoropropyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(cyclohexylmethyl)acetamide 0
                                      2-[(3R,6aR,8S,10aR)-3-hydroxy-1-[4-oxanyl(oxo)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-ethylacetamide 0
                                      2-[(3R,6aR,8S,10aR)-3-hydroxy-1-[oxo(propylamino)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]acetic acid 0
                                      2-[(3R,6aR,8S,10aR)-3-hydroxy-1-methyl-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-cyclobutylacetamide 0
                                      2-[(3R,6aR,8S,10aR)-3-hydroxy-1-methylsulfonyl-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(phenylmethyl)acetamide 0
                                      2-[(3R,6aS,8R,10aS)-1-(cyclopentanecarbonyl)-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N,N-dimethylacetamide 0
                                      2-[(3R,6aS,8R,10aS)-1-(cyclopentylmethyl)-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[3-(dimethylamino)propyl]acetamide 0
                                      2-[(3R,6aS,8R,10aS)-3-hydroxy-1,2,3,4,6,6a,8,9,10,10a-decahydropyrano[2,3-c][1,5]oxazocin-8-yl]acetic acid methyl ester 0
                                      2-[(3R,6aS,8R,10aS)-3-hydroxy-1-(3,3,3-trifluoropropyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]acetic acid methyl ester 0
                                      2-[(3R,6aS,8R,10aS)-3-hydroxy-1-(4-oxanylmethyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(cyclopropylmethyl)acetamide 0
                                      2-[(3R,6aS,8R,10aS)-3-hydroxy-1-(oxane-4-carbonyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-ethylacetamide 0
                                      2-[(3R,6aS,8R,10aS)-3-hydroxy-1-methyl-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-cyclobutylacetamide 0
                                      2-[(3R,6aS,8R,10aS)-3-hydroxy-1-methylsulfonyl-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-benzylacetamide 0
                                      2-[(3R,6aS,8S,10aS)-1-(cyclopentylmethyl)-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[3-(dimethylamino)propyl]acetamide 0
                                      2-[(3R,6aS,8S,10aS)-1-[cyclopentyl(oxo)methyl]-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N,N-dimethylacetamide 0
                                      2-[(3R,6aS,8S,10aS)-3-hydroxy-1,2,3,4,6,6a,8,9,10,10a-decahydropyrano[2,3-c][1,5]oxazocin-8-yl]acetic acid methyl ester 0
                                      2-[(3R,6aS,8S,10aS)-3-hydroxy-1-(3,3,3-trifluoropropyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(cyclohexylmethyl)acetamide 0
                                      2-[(3R,6aS,8S,10aS)-3-hydroxy-1-(4-oxanylmethyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(cyclopropylmethyl)acetamide 0
                                      2-[(3R,6aS,8S,10aS)-3-hydroxy-1-[4-oxanyl(oxo)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-ethylacetamide 0
                                      2-[(3R,6aS,8S,10aS)-3-hydroxy-1-methyl-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(1S)-1-phenylethyl]acetamide 0
                                      2-[(3R,6aS,8S,10aS)-3-hydroxy-1-methyl-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-cyclobutylacetamide 0
                                      2-[(3R,6aS,8S,10aS)-3-hydroxy-1-methyl-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-cyclopentylacetamide 0
                                      2-[(3R,6aS,8S,10aS)-3-hydroxy-1-methylsulfonyl-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(phenylmethyl)acetamide 0
                                      2-[(3S,6aR,8R,10aR)-1-(cyclopentylmethyl)-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[3-(dimethylamino)propyl]acetamide 0
                                      2-[(3S,6aR,8R,10aR)-3-hydroxy-1,2,3,4,6,6a,8,9,10,10a-decahydropyrano[2,3-c][1,5]oxazocin-8-yl]acetic acid methyl ester 0
                                      2-[(3S,6aR,8R,10aR)-3-hydroxy-1-(1-oxopropyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-methylacetamide 0
                                      2-[(3S,6aR,8R,10aR)-3-hydroxy-1-(3,3,3-trifluoropropyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(cyclohexylmethyl)acetamide 0
                                      2-[(3S,6aR,8R,10aR)-3-hydroxy-1-(3,3,3-trifluoropropyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]acetic acid methyl ester 0
                                      2-[(3S,6aR,8R,10aR)-3-hydroxy-1-(4-oxanylmethyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(cyclopropylmethyl)acetamide 0
                                      2-[(3S,6aR,8R,10aR)-3-hydroxy-1-[4-oxanyl(oxo)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-ethylacetamide 0
                                      2-[(3S,6aR,8R,10aR)-3-hydroxy-1-methyl-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-cyclobutylacetamide 0
                                      2-[(3S,6aR,8S,10aR)-1-(cyclopentylmethyl)-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[3-(dimethylamino)propyl]acetamide 0
                                      2-[(3S,6aR,8S,10aR)-1-[cyclopentyl(oxo)methyl]-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N,N-dimethylacetamide 0
                                      2-[(3S,6aR,8S,10aR)-3-hydroxy-1,2,3,4,6,6a,8,9,10,10a-decahydropyrano[2,3-c][1,5]oxazocin-8-yl]acetic acid methyl ester 0
                                      2-[(3S,6aR,8S,10aR)-3-hydroxy-1-(3,3,3-trifluoropropyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(cyclohexylmethyl)acetamide 0
                                      2-[(3S,6aR,8S,10aR)-3-hydroxy-1-(3,3,3-trifluoropropyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]acetic acid methyl ester 0
                                      2-[(3S,6aR,8S,10aR)-3-hydroxy-1-(4-oxanylmethyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(cyclopropylmethyl)acetamide 0
                                      2-[(3S,6aR,8S,10aR)-3-hydroxy-1-(oxane-4-carbonyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-ethylacetamide 0
                                      2-[(3S,6aR,8S,10aR)-3-hydroxy-1-methyl-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-cyclobutylacetamide 0
                                      2-[(3S,6aS,8R,10aS)-1-(cyclopentylmethyl)-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[3-(dimethylamino)propyl]acetamide 0
                                      2-[(3S,6aS,8R,10aS)-1-[cyclopentyl(oxo)methyl]-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N,N-dimethylacetamide 0
                                      2-[(3S,6aS,8R,10aS)-3-hydroxy-1,2,3,4,6,6a,8,9,10,10a-decahydropyrano[2,3-c][1,5]oxazocin-8-yl]acetic acid methyl ester 0
                                      2-[(3S,6aS,8R,10aS)-3-hydroxy-1-(3,3,3-trifluoropropyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(cyclohexylmethyl)acetamide 0
                                      2-[(3S,6aS,8R,10aS)-3-hydroxy-1-(4-oxanylmethyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(cyclopropylmethyl)acetamide 0
                                      2-[(3S,6aS,8R,10aS)-3-hydroxy-1-(propylcarbamoyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]acetic acid 0
                                      2-[(3S,6aS,8R,10aS)-3-hydroxy-1-[4-oxanyl(oxo)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-ethylacetamide 0
                                      2-[(3S,6aS,8R,10aS)-3-hydroxy-1-methyl-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-cyclobutylacetamide 0
                                      2-[(3S,6aS,8R,10aS)-3-hydroxy-1-methylsulfonyl-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(phenylmethyl)acetamide 0
                                      2-[(3S,6aS,8S,10aS)-1-(cyclopentylmethyl)-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[3-(dimethylamino)propyl]acetamide 0
                                      2-[(3S,6aS,8S,10aS)-1-[cyclopentyl(oxo)methyl]-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N,N-dimethylacetamide 0
                                      2-[(3S,6aS,8S,10aS)-3-hydroxy-1,2,3,4,6,6a,8,9,10,10a-decahydropyrano[2,3-c][1,5]oxazocin-8-yl]acetic acid methyl ester 0
                                      2-[(3S,6aS,8S,10aS)-3-hydroxy-1-(3,3,3-trifluoropropyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(cyclohexylmethyl)acetamide 0
                                      2-[(3S,6aS,8S,10aS)-3-hydroxy-1-(3,3,3-trifluoropropyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]acetic acid methyl ester 0
                                      2-[(3S,6aS,8S,10aS)-3-hydroxy-1-(4-oxanylmethyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(cyclopropylmethyl)acetamide 0
                                      2-[(3S,6aS,8S,10aS)-3-hydroxy-1-[4-oxanyl(oxo)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-ethylacetamide 0
                                      2-[(3S,6aS,8S,10aS)-3-hydroxy-1-[oxo(propylamino)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]acetic acid 0
                                      2-[(3S,6aS,8S,10aS)-3-hydroxy-1-methyl-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-cyclobutylacetamide 0
                                      2-chloro-N-[2-(2,2-dimethyl-4-phenyl-4-oxanyl)ethyl]acetamide 0
                                      3-imino-1,5,5-trimethyl-2-oxabicyclo[2.2.1]heptane-4,7,7-tricarbonitrile 0
                                      Abyssomicin I 0
                                      Aurothioglucose 17
                                      Avermectin A2a aglycone 0
                                      Avermectin A2b aglycone 0
                                      Avermectin B2b aglycone 0
                                      Bis(2,3-epoxycyclopentyl)ether 0
                                      Bisabolol oxide A 0
                                      Caespitol 0
                                      Chlorochrymorin 0
                                      Chrycorin 0
                                      Clarycet 0
                                      Cochlioquinone A 0
                                      Coronarian 0
                                      Cunaniol 0
                                      Cytosporin D 0
                                      D-1,5-Anhydrofructose 0
                                      Daucol 0
                                      Epomediol 4
                                      Epoxyeremopetasinorol 0
                                      Heptachlor epoxide 112
                                      Hymenoxon 0
                                      Ichthyotherol 0
                                      Isocaespitol 0
                                      Linalool oxide (trans-pyranoid) 0
                                      Linalool oxide III 0
                                      Linalool oxide pyranoside 0
                                      Microhelenin A 0
                                      N-(4-\{4-amino-1-[1-(tetrahydro-2H-pyran-4-yl)piperidin-4-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl\}-2-methoxyphenyl)-1-methyl-1H-indole-2-carboxamide 0
                                      N-(5-\{[(5-tert-butyl-1,3-oxazol-2-yl)methyl]sulfanyl\}-1,3-thiazol-2-yl)tetrahydro-2H-pyran-4-carboxamide 0
                                      N-[2-morpholin-4-yl-1-(morpholin-4-ylmethyl)ethyl]-3-nitro-5-(3,4,5-trihydroxy-6-hydroxymethyltetrahydropyran-2-yloxy)benzamide 0
                                      N-\{3-[4-(3-aminopropyl)piperazin-1-yl]propyl\}-3-(2-thiophen-2-ylacetylamino)-5-(3,4,5-trihydroxy-6-hydroxymethyltetrahydropyran-2-yloxy)benzamide 0
                                      N-tert-butyl-7,7-dimethyl-2-oxo-1,8-dioxaspiro[4.5]decane-4-carboxamide 0
                                      Oryzalic acid A 0
                                      Oxychlordane 0
                                      PF-4800567 0
                                      Plaunol D 0
                                      Smardaesidin C, (rel)- 0
                                      Tepraloxydim 0
                                      Tetrahydro-2,5-dimethyl-2H-pyranmethanol 0
                                      Tritoniopsin A, rel- 0
                                      Tritoniopsin B, rel- 0
                                      Tritoniopsin C, rel- 0
                                      Tritoniopsin D 0
                                      Vulgarolide 0
                                      \{(2R,3S,4S,5S)-3,4-dihydroxy-5-(hydroxymethyl)-5-[(2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-methoxytetrahydro-2H-pyran-2-yloxy]tetrahydrofuran-2-yl\}methyl nonanoate 0
                                      alpha-Bisabolol oxide C 0
                                      auricin 0
                                      bafilomycin A1 70
                                      daibuoxide 0
                                      gilteritinib 0
                                      glutaric anhydride 0
                                      hygrolidin 0
                                      indanomycin 0
                                      lasalocid 1
                                      linaloyl oxide 0
                                      marinolic acid C 0
                                      methyl 2-[(3R,6aR,8S,10aR)-3-hydroxy-1-(3,3,3-trifluoropropyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]acetate 0
                                      methyl 2-[(3R,6aS,8S,10aS)-3-hydroxy-1-(3,3,3-trifluoropropyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]acetate 0
                                      methyl 2-[(3S,6aS,8R,10aS)-3-hydroxy-1-(3,3,3-trifluoropropyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]acetate 0
                                      mupirocin 0
                                      myriaporone 3 0
                                      oxane + 0
                                      pederin 0
                                      rose oxide + 0
                                      saracatinib 11
                                      venetoclax 7
paths to the root